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Zusammenfassung 
Alopecia Areata (AA) ist eine organspezifische Autoimmunerkrankung, welche 
Haarfollikel in der anagenen Phase angreift und durch eine peri- und intrafollikuläre 
Infiltration mit CD4+ und CD8+ T Zellen charakterisiert ist.  
Die wirkungsvollste Behandlungsmethode besteht in der Induktion eines milden 
chronischen Kontaktekzems durch die topikale Applikation eines Kontaktallergens 
wie Sqaricdibutylester, das über mehrere Monate appliziert wird. Die Mechanismen, 
welche dem therapeutischen Effekt eines Kontaktekzems bei AA zu Grunde liegen, 
sind weitgehend unbekannt. Es gibt jedoch Hinweise auf eine Expansion sogenannter 
myeloider Suppressorzellen, die Proliferation und Aktivierung von T-Zellen hemmen. 
Andererseits kann auch eine Blockade kostimulatorischer Moleküle der T-
Zellaktivierung, wie z.B. CD44, therapeutisch wirksam sein.  
Aktivierte T-Zellen sind durch eine Hochregulation der Expression von CD44 
charakterisiert. Dies führt zu einer Steigerung der T-Zellproliferation und erhöht 
deren migratorisches Potenzial. Es wurde postuliert, dass diese Effekte auf eine 
Kooperation von CD44 mit CD49d zurückzuführen sind. Um diese Hypothese zu 
überprüfen und die zu Grunde liegenden Mechanismen zu klären, habe ich zwei 
Leukämiezelllinien, EL4 und Jurkat, die entweder CD44 (Jurkat) oder CD49d (EL4) 
exprimieren mit der CD44 bzw. CD49d cDNA transfiziert. Zusätzlich habe ich CD44 
und CD49d Mutanten erstellt, die die Interaktion dieser beiden Moleküle miteinander 
oder die Interaktion mit dem Zytoskelett oder zytoplasmatischen Kinasen verhindern. 
Erste Befunde bestätigen die funktionelle Aktivität der transfizierten  Moleküle und 
belegen, insbesondere im Kontext mit der Motilität der T-Zellen, das essentielle 
Zusammenspiel von CD44 und CD49d und ergaben Hinweise auf beteiligte 
Zytoskelett- und Signaltransduktionsmoleküle. Entsprechende Untersuchungen der 
transfizierten Leukämiezelllinien zum Einfluss von CD44 und CD49d auf die T-
Zellproliferation belegten, dass das gewählte Modell zur Beantwortung der Frage 
geeignet ist. Untersuchungen zum molekularen Mechanismus sind noch nicht 
abgeschlossen. 
Diese Befunde deuten auf eine Kooperation von CD44 und CD49d in der T-
Zellmigration, -aktivierung und -proliferation hin. Eine Blockade von CD44 und 
CD49d  könnte einen Ansatzpunkt für die Therapie von Autoimmunerkrankungen 
darstellen. 
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Um die Frage zu beantworten, ob myeloide Suppressorzellen maßgeblich für den 
therapeutischen Effekt eines chronischen Kontaktekzems verantwortlich sind, habe 
ich zerst gezeigt, dass eine Behandlung mit trans-Retinolsäure den therapeutischen 
Effekt eines chronischen Kontaktekzems aufhebt. Es ist bekannt, dass trans-
Retinolsäure  myeloide Suppressorzellen in die Differenzierung treibt und sie dabei 
ihre suppressive Eigenschaft verlieren. Somit belegt dieser Versuch, dass myeloide 
Suppressorzellen maßgeblich am Therapieeffekt eines Kontaktekzems bei AA 
beteiligt sind. 
Um die Mechanismen zu klären, mittels derer ein chronisches Kontaktekzem bzw. 
myeloide Suppressorzellen mit den autoreaktiven T-Zellen der AA interferieren, 
wurden die Effekte einer Kontaktallergenbehandlung  mit denen von in vitro 
Kokulturen von T-Zellen aus  AA Mäusen mit myeloiden Suppressorzellen von 
Kontaktallergen-behandelten Mäusen verglichen. Kontaktallergenbehandlung und 
myeloide Suppressorzellen inhibieren die Proliferation der T-Zellen von AA Mäusen. 
Es wurde eine leichte Reduktion der ξ Kettenexpression und eine stark verminderte 
Aktivierung von Lck und Zap 70 beobachtet. und, weniger ausgeprägt, einer 
Reduktion der c-jun- und MAPK-Signalwege begleitet. Der stärkste Effekt wurde in 
Anwesenheit von AA-Hautlysaten, eines autoantigenen Stimulus, gesehen. Die 
Proliferation wurde aber auch bei T-Zellrezeptor-unabhängiger Stimulation durch 
PMA und Ionomycin gehemmt. Dieser Befund belegt, dass ein Kontaktallergen bzw. 
myeloide Suppressorzellen zumindest teilweise unabhängig vom T-Zellrezeptor-
Komplex wirken. Tatsächlich steigern ein Kontaktallergen bzw. myeloide 
Suppressorzellen die Aktivierung verschiedener proapoptotischer Moleküle, die an 
der mitochondrialen Apoptose beteiligt sind, und hemmen den anti-apoptotischen 
PI3K/Akt Weg. Der letzt genannte Effekt korreliert mit der TNFα-Sekretion der 
myeloide Suppressorzellen und TNFRI-Expression in Kontaktallergen behandelten T-
Zellen von AA Mäusen. 
Zusammenfassend kann gesagt werden, dass die Kontaktallergenbehandlung 
myeloide Suppressorzellen induziert, welche T-Zellaktivierung inhibieren und dazu 
beitragen Apoptoseresistenz autoimmuner T-Zellen  zu senken, indem sie die 
Aktivierung von pro-apoptotischen Proteinen induzieren. Kontaktallergen-induzierte 
myeloiden Suppressorzellen erscheinen daher für die Therapie organspezifischer 
Autoimmunerkrankungen in besonderer Weise geeignet. 




1.1 Skin and Hair 
  
The skin is the largest organ of the integumentary system and it provides a protective 
barrier that keeps microbes out and essential body fluids in (1). Skin is composed of 
three primary layers: the epidermis, which provides water proofing and serves as a 
barrier to infection; the dermis, which serves as a location for the appendages of skin 
including  hair follicles and the hypodermis (subcutaneous adipose layer) (2). Hair is 
a filamentous biomaterial, which grows from follicles found in the dermis of the skin 
and is primarily composed of protein, notably keratin. Hair is one of the defining 
characteristics of the mammalian class since it is exclusively found in mammals. 
1.1.1 Hair Structure 
A cross section of the hair may be divided roughly into three zones:  
 Cuticle: it is the outermost part of the hair shaft. It is a hard shingle-like layer of 
overlapping cells. The hair cuticle is the first line of defense against all forms of 
damage; it acts as a protective barrier for the softer inner structure including 
the medulla and cortex and also controls the water content of the fiber (3).  
 Cortex: it contains the keratin bundles in cell structures and makes up the majority 
of the hair shaft. It is the cortex that gives hair its special qualities such as elasticity 
and curl.  
 Medulla: it is also called the pith or marrow of the hair. It is composed of round 
cells, two to five rows across. Thick or coarse hair usually contains a medulla while 
fine hair lacks a medulla (4). 
Hair grows from a follicular structure called hair follicle (HF) which serves as a hair 
root. The mature HF is a complex structure, composed of several concentric cylinders 
of epithelial cells, known as root sheaths which surrounds the hair shaft (5) The HF 
contains at its base a ball of specialized dermal cells, the dermal papilla which is fed 
by the blood stream and plays a very crucial role in the regulation of successive cycles 
of postnatal hair growth. Signals from the dermal papilla instruct epithelial stem cells 
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residing in the bulge region of the follicle to migrate to the base of the follicle, where 
they surround the dermal papilla, forming the hair matrix in response to further  
signals from dermal papilla matrix cells proliferate and differentiate to form hair shaft 
and inner root sheath (Scheme 1). Melanocytes also reside in HF and deposit pigment 
granules into the hair shaft as it forms (6-8). Keratins are a major structural 
component of the hair follicle. The hair shaft is a highly keratinized tissue formed 
within the hair follicle. When the specific epithelial cells in the hair shaft, known as 
trichocytes, pass through the keratinizing zone, keratinization actively occurs and the 
rigid hair shaft is generated (9). In humans, a total of 17 functional hair keratin genes 
(11 type I and 6 type II) have been identified. It has been shown that these hair 
keratins, except for one type II keratin K84 (Hb4), are abundantly and sequentially 
expressed in the hair shaft (10, 11, 12). 
 
 
Scheme1.  Structure of hair follicle. 
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1.1.2 Hair follicle morphogenesis 
 
The formation of hair follicles occurs during embryogenesis through a series of 
signals between dermal cells and overlying surface epithelial cells resulting in 
differentiation of the hair shaft, root sheaths, and dermal papilla (13). The epithelial 
cells that receive this ‘first dermal signal’ form a thickening of columnar cells known 
as a placode. Subsequently, a signal from the placode leads to the formation of a 
mesenchymal (dermal) condensate just beneath the placode. In response to a ‘second 
dermal signal’ from the dermal condensate, the epithelial placode cells proliferate and 
invade the dermis, eventually surrounding the dermal condensate, which develops into 
dermal papilla. Further proliferation and differentiation of the epithelial cells results in 
the formation of the inner root sheath and hair shaft of the mature hair follicle. 
Finally, the epithelial cells undergo proliferation and eventual differentiation into 
several distinct layers (14, 15) (Scheme 2). 
 
Scheme2. Follicular morphogenesis (17). 
1.1.3 Hair Growth cycle 
Each hair follicle undergoes a cycle of activity. The hair grows to a maximum length, 
then hair growth ceases and the hair is shed and replaced. At any one time we have 
only around 85% of our hair growing, the rest being in the resting stages. The hair 
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growth cycle has three distinctive phases (Scheme 3); Anagen: the period of active 
growth; Catagen: the period of breakdown and change; Telogen: the resting stage 
before resumption of growth 
1.1.3.1 Anagen: The epidermal cells surrounding the dermal papilla form the 
germinal matrix or root of the hair. These cells are constantly dividing, and as new 
cells are formed they push the older ones upwards where they begin to change shape. 
By the time the cells are about one-third of the way up the follicle they are dead and 
fully keratinized (16). In the anagen phase, the HF grows downward and forms the 
matrix region at its base. These matrix cells actively proliferate and differentiate into 
several distinct cell types, giving rise to the companion layer, the inner root sheath, 
and the hair shaft (17). A scalp hair will grow actively for between one and a half and 
seven years (three years being an average growth period). The average growth rate is 
about half an inch per month. On average 85% of follicles are in the anagen stage. 
1.1.3.1 Catagen: This is the end of the active growth period, and is marked by 
changes occurring in the follicle. The hair stops growing and becomes detached from 
the base of the follicle forming a club hair. The hair bulb begins to break down, 
resulting in the follicle becoming shorter. A small section of the outer root sheath 
remains in contact with the group of cells that formed the papilla. This period of 
breakdown or change lasts about three weeks. As the inner root sheath breaks down, 
the hair remains in the follicle due to its shape. On average, 1% of follicles are in the 
catagen stage. In the catagen phase, the lower portion of the HF undergoes apoptosis 
and regresses toward the permanent portion, before the HF returns to the telogen 
phase. Importantly, the mesenchyme-derived dermal papilla regresses and descends 
with the lower portion of the HF during catagen (17). 
1.1.3.2 Telogen: The section of remaining root sheath still in contact with the papilla 
is known as the secondary or root germ. It is from this root germ that a new hair can 
grow. The shortened follicle rests for about three months. The hair may be brushed 
out at this time or at the onset of anagen. On average 14% of follicles are in the 
telogen stage. 
 After the telogen stage the cycle returns to anagen and the root germ begins to grow 
downwards and forms a new bulb around the dermal papilla. It is the lower end of the 
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germ that forms the new bulb, producing a new hair. The upper part of the germ forms 
the new cells that lengthen the follicle below the club hair. The new hair may push the 
old hair out; therefore sometimes one may see two hairs in the same follicle (18, 19). 
 
Scheme3. The hair cycle:  The stages of the hair cycle are depicted, starting from the first 
postnatal anagen, when the hair shaft is growing and protruding through the skin surface. Follicles 
progress synchronously to the destructive (catagen) phase, during which the lower two-thirds of the 
follicle undergo apoptosis and regress. The dermal papilla is brought to rest below the bulge-stem-cell 
compartment, and after the resting (telogen) phase, a critical threshold of activating factors is reached 
and the stem cells become activated to regrow the hair (17). 
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1.2 Diseases associated with hair 
 
The loss of hair is known as Alopecia, this disease is not life threatening but the 
pressures of an image orientated society can make hair loss psychologically 
devastating for those affected, their families, and friends. 
The loss of hair could be either permanent or temporary, based on these clinical 
observations; alopecia is further classified broadly as: 
 Scarring (cicatricial) alopecia:  hair loss associated with fibrosis and scar tissue that 
replaces and often permanently destroys the hair follicle. 
 Non-Scarring alopecia: hair loss without permanent destruction of the hair follicle 
(20). 
1.2.1 Scarring (cicatricial ) Alopecia 
This disorder destroys the hair follicle and replaces the follicle with a scar of fibrous 
tissue causing permanent hair loss. In some cases, the hair loss is gradual and no 
symptoms are evident for long periods. In other cases, scarring alopecia causes are 
associated with severe itching, burning and pain which are rapidly progressive. The 
inflammation destroys the follicle below the skin surface but above the skin surface 
generally not much inflammation is visible. Studies leads to a hypothesis that scarring 
alopecia involves the malfunctioning of one of the hair structure machineries, which 
includes the stem cell rich region in the hair follicle and the outer root sheath (21). 
Most kinds of the alopecia of the scarring type involve the inflammatory infiltration 
of different immune cells and affecting one of these structures. 
On the basis of the predominant type of inflammatory cell component, the scarring 
alopecia is further classified into three groups: Lymphocytic scarring alopecia, 
Neutrophilic scarring alopecia and Mixed inflammatory scarring alopecia  
 
1.2.1.1 Lymphocytic scarring alopecia: It is associated with infiltration of 
lymphocytes into structural component of hair. The most common example of this 
type of alopecia is Discoid Lupus Erythematosus (DLE) or Chronic Cutaneous Lupus 
Erythematosus. Clinically DLE is characterized by ill defined patches of alopecia, 
with decreased follicular orifices, scale erythema, follicular plugging, depigmentation 
and atrophy (22). Some studies suggest that exposure to ultraviolet light provokes or 
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incites keratinocyte apoptosis and a reactive T-cell- or immune-complex-mediated 
response. 
 
1.2.1.2 Neutrophilic scarring alopecia:  It involves intrafollicular and perifollicular 
neutrophil infiltration. One of the examples of this kind is Folliculitis Decalvans, 
characterized by inflamed hair follicles that discharge pus. This scarring alopecia is an 
outcome of the patient’s susceptibility to infections due to systemic or local immune 
deficits and Staphlococcus aureus strain related properties. (Both acquired and 
inherited immune disturbances are associated with folliculitis decalvans) (23). 
 
1.2.1.3 Mixed inflammatory scarring alopecia: It involves both neutrophil and 
lymphocytes infilteration in intrafollicular and interfollicular regions. Example 
includes, Folliculitis (Acne) Keloidalis, early in this disease there is follicular 
dialation with neutrophil and follicular rupture, late lesions shows perifollicular 
granulomas around naked hair shafts mixed with a lymphoplasmacellular cell 
infiltrate and hypertrophic scar with broad eosinophilic hyalinized keloidal collagen 
bundles. Sebaceous glands are absent in this disease (24-26). 
 
1.2.2 Non- Scarring Alopecia:  
Non scarring alopecia involves temporal hair loss. Hair follicles are intact and are not 
damaged. Clinically in non-scarring alopecia follicular orifices are grossly apparent 
on the scalp and histo-pathologically the follicular units are intact. Hence hair re-
growth is possible in non-scarring alopecia. This kind of alopecia involves different 
kinds: 
 
1.2.2.1 Androgenetic alopecia: It is the most common type of hair loss. It is a 
disorder of dominant inheritance with variable penetrance (27, 28) affecting 
approximately half of the population by the age of 50 years, of both the sexes (28, 
29). Clinically it is a patterned alopecia, i.e. it is characterized by bitemporal recession 
and vertex balding in men (30) and in women (female pattern hair loss) by diffuse 
hair thinning of the crown with an intact frontal hair line (31). The total numbers of 
hair follicle remains unchanged but are genetically programmed, under the influence 
of androgens to undergo miniaturization (28, 32-34).  
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1.2.2.2 Telogen effluvium: it is a diffuse form of alopecia, in which the hair falling 
may be acute or chronic. Acute telogen effluvium can occur in both male and female 
and can be triggered by numerus factors like major surgery, injury, severe illness, 
childbirth, crash diet and numerous medications (33,35).  
 
1.2.2.3 Traction alopecia: It is a non-inflammatory, non-scarring alopecia which 
occurs due to mechanical damage. Clinically, the hair loss is often seen at the margins 
of the scalp, involving the frontal, temporal and parietal regions. In early traction 
alopecia the hair loss is temporary; in late traction alopecia there is marked loss of the 
terminal follicles with preservation of the vellus hairs and sebaceous glands and can 
lead to scarring process and thus permanent hair loss (36). 
 
1.2.2.4 Alopecia areata:  Alopecia areata (AA) is an inflammatory hair loss disease 
that can affect men, women and children. Circumstantial evidence suggests alopecia 
areata is an autoimmune disease where cells of an individual's own immune system 
prevent hair follicles from producing hair fiber. Alopecia affects certain stages of hair 
growth cycle the most affected stage could be the active phase, anagen stage which is 
characterized by active DNA synthesis and melanogenesis. 
Clinically, it is characterized by sudden onset of patches of nonscarring hair loss,   
with ‘exclamation-point’ hairs.  It may involve the entire scalp (alopecia totalis) and 
body hair (alopecia universalis), nail changes (pitting, thickening and ridging) may be 
seen. The early active stage is characterized by a peribulbar lymphoid cell infiltrate 
(33, 37) affecting the terminal hair follicles (35) and may invade the follicular 
epithelium and the matrix, as well as extend above the hair bulb and into fibrous tracts 
(37). Initially, the terminal hairs are attacked, but subsequently also the vellus hairs 
become involved. Eosinophils (38) and plasma cells may be present (39, 37).  There is 
a 70–90% ‘shift out of anagen’ of the hair follicles into catagen or telogen phase (33), 
but the number of hair follicles is unchanged. In longstanding (chronic) stages, with 
repeated episodes, the peribulbar lymphoid cell infiltrate also involves miniaturized 
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1.3 Alopecia areata as an autoimmune disease 
Alopecia areata (AA) is a heterogeneous disease characterized by non scarring hair 
loss on the scalp or any hair-bearing surface. It is one of the most frequently occurring 
organ-restricted autoimmune diseases in humans targeted to hair follicle (40).  
However, the antigenic targets, mechanisms, and consequences of autoimmune attack 
in AA have yet to be determined, but the evidence that autoimmunity may play a role 
in AA is dependant upon following factors: 
i) Its association with other autoimmune diseases, like vitiligo and thyroid diseases 
including Hashimoto’s Thyroiditis also, anti-thyroid antibodies and thyroid 
microsomal antibodies have been found in AA patients (41, 42).  
ii)   Response of AA patient to immunosuppressive or immunomodulatory therapy.   
iii) The characteristic infiltration of lymphocytes is present in and around the hair 
bulbs in active disease (43). In AA the infiltrate consists predominantly of activated T 
lymphocytes along with macrophages and Langerhans cells (44-46). Both CD4+ and 
CD8+ T lymphocytes are observed peri- and intra-follicularly. Studies involving 
injections of separated CD4+ and CD8+ or both cells together demonstrated that 
injection of purified single cell type alone did not result in hair loss, in contrast 
mixture of CD4+ and CD8+ T cells results in significant loss of hair. These results 
suggest that both CD4+ and CD8+ T cells have an important role in the pathogenesis 
of AA (47). An increased expression has been observed of class I MHC and class II 
MHC antigens in and around the lesions.  
iv) Pro-inflammatory changes occur both in the skin and in immune system organs. 
Inflammatory markers include the upregulation of expression of intercellular cell 
adhesion molecule (ICAM) and endothelial leukocyte adhesion molecule (ELAM) on 
the endothelium of blood vessels closely associated with affected hair follicles (48-
50). Changes in cytokine levels, particularly activating cytokines such as interleukin 2 
(IL- 2) and interferon-γ (IFN-γ) have been noted in patients with AA compared to 
normal controls (51). 
v) Associations between specific human leukocyte antigen (HLA genes) and AA lend 
further circumstantial evidence that autoimmune mechanisms are involved in the 
pathogenesis of disease. Normal hair follicle epithelium typically does not express the 
HLA class I antigen A, B and C. There is a concomitant increased expression of HLA 
class I (HLA-A, B, and C) and class II (HLA-DR) antigens in AA, (52, 53). In 
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particular, HLA class II alleles – DR4, DR5 (DR11), DR6 (54-61), and HLA-DQ3 
(including both subtypes DQB1*0301 (DQ7) and DQB1*0302 (DQ8)) (54-56, 64, 65) 
have been most consistently associated with AA. Furthermore, specific HLA 
associations have been reported as markers of clinical sub-types of AA (64). In the 
more severe forms of the disease–alopecia totalis (AT) and alopecia universalis (AU) 
– DRB1*0401 (DR4) and DQB1*0301(DQ7) are expressed with increased frequency 
(64). Hair follicles in the anagen phase are recognized sites of immune privilege. HF 
immune privilege is characterized by down regulation of MHC class I expression and 
strong local expression of immunosuppressants. HF appear to maintain immune 
privilege by actively suppressing natural killer cells (66) and  showed that the NK cell 
inhibitor, macrophage migration inhibitor factor, is strongly expressed by HF 
epithelium and that very few NK cells are observed in and around normal anagen HF 
compared to AA, in which they are prominently aggregated. A collapse of the 
immune privilege (IP) of the hair follicle results in the loss of hair, as seen in patients 
with AA (Scheme 4). 
 
 
Scheme4. A model of immune privilege collapse in AA pathogenesis: Both a normal 
anagen (growing) hair follicle (A) and a hair follicle in AA (B) are shown. MHC class I molecules are 
expressed on the epidermis, and on the most superficial (distal) portion of the normal hair follicle 
epithelium. The inferior (proximal) portions of the hair follicle are immune privileged and deficient in 
expression of MHC classes I and II as well as APCs. By contrast, the AA anagen hair follicle expresses 
MHC class I and II molecules throughout the follicular epithelium, including the portion adjacent to the 
dermal papilla of the hair follicle. Active AA also exhibits a perifollicular infiltrate of CD4+ T cells and 
an intrafollicular infiltrate of CD8+ T cells. IRS, inner root sheath; ORS, outer root sheath (65). 
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Experimental studies also give stronger evidence that autoimmune phenomenon is 
involved in AA, for example lesional scalp skin from AA patients grafted onto nude 
(athymic) mice shows regrowth of hair, suggesting a loss of inhibition by T cells. 
These experiments strongly suggest that the key mediators of AA reside outside the 
follicle itself. Given that lesional skin grafts are able to regrow hair in an athymic 
host, functional T cell populations appear to be involved in the pathogenesis of this 
disease (67). The strongest evidence implicating autoimmune mechanisms in the 
pathophysiology of alopecia areata has been provided by studies involving mice with 
severe combined immunodeficiency (SCID) (68). AA was induced on human scalp 
explants transplanted onto SCID mice by injection of autologous T lymphocytes from 
lesional skin. In particular, only T lymphocytes cultured with hair follicle homogenate 
and antigen presenting cells were capable of inducing AA in scalp explants. Both the 
clinical and histopathologic features of AA were reproduced in this model, including 
hair loss, perifollicular T lymphocyte infiltration, and expression of HLA-DR and 
ICAM-1 in the follicular epithelium. The induction of these changes was not a 
nonspecific effect of T cell activation, as lesions could not be produced by injection of 
IL-2 activated T cells from peripheral blood or scalp. Moreover, the fact that these 
changes could not be induced by lesional scalp T cells that were not cultured with 
follicular homogenate strongly suggests that the T lymphocytes involved in AA are 
reacting to specific follicular antigens (68). 
 
1.4  Treatment of AA 
There are several potential therapeutic drugs for treatment of alopecia areata. 
 
1.4.1 Immunosuppressive 
 Corticosteroids: corticosteroids are known to exert a strong inhibitory effect on the 
activation of T Lymphocytes, and also these can result in Th-1 mediated immune 
attack on the hair follicle in AA.  Topical, intralesional, and systemic corticosteroids 
have been used to treat AA, with different side-effects. But the rate of treatment 
success was not statistically significant (70-76). This treatment is only indicated in 
patchy AA with longstanding bald areas. It’s a painful procedure and can lead to 
permanent atrophy after injection. Whereas, initially, oral corticosteroids were used 
daily or every other day for several months (30 and 150 mg daily) giving rise to 
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unacceptable side effects such as hypertension, diabetes, immunosuppression, 
osteoporosis and proneness to thrombosis. Taken together, corticosteroids treatment is 
reasonable in exceptional, selected cases of AA, but has potentially serious side-
effects. 
 PUVA: Several studies have examined treatment of AA with PUVA using either 
oral or topical application of 8-methoxypsoralen (8-MOP) with ultraviolet A radiation 
(UVA) on the scalp or the whole body (77-83). There are a large number of 
recurrences (between 30% and 50% of successfully treated patients).due to the fact 
that regrown hair inhibits UVA radiation from reaching the skin. Long treatment with 
PUVA can lead to high risk of skin malignancies  
  Tacrolimus: FK506 is an immunosuppressive agent that can be applied topically to 
the skin. FK506 suppresses IL-2 production and release in activated T cells. 
Subsequently, activation and proliferation of T cells are inhibited (84). Therefore, 
FK506 is a promising candidate for the treatment of AA. In the C3H/HeJ mice model 
of AA, topically applied FK506 induces hair regrowth (85,86), accompanied by 
reduced peri- and intrafollicular infiltrates of CD4+ and CD8+ T cells and decreased 
expression of MHC class I, MHC class II and ICAM-1 on hair follicle epithelium. 
These encouraging results obtained in animal models suggested that topical 
application of FK506 could be effective in the treatment of human AA. 
 
1.4.2 Immunomodulatory 
 Squaric acid dibutylester (SADBE): AA has been treated with contact sensitizers 
for more than 20 years. Dinitrochlorobenzene (DNCB) was the first to be used (87), 
but because it has been shown to be mutagenic in the Ames test, it can no longer be 
recommended (88, 89). Today diphenylcyclopropenone (DCP) or squaric acid 
dibutylester (SADBE), which are not mutagenic in the Ames test, are widely used. 
Treatment with contact sensitizers are preceded by sensitization of the patient with 
2% SADBE solution on a small area of the scalp. Two weeks later, treatment is 
initiated by applying a 0.001% SADBE solution, followed by weekly applications of 
increasing concentrations until a mild eczematous reaction is obtained. In this way, an 
appropriate eliciting concentration of SADBE is identified for each patient. This 
concentration is then applied once a week to induce a mild eczematous reaction 
characterized by itching and erythema, without blistering or oozing. SADBE is used 
                                                                                                                      Introduction 
 19
in those patients who become tolerant to DCP. Initial hair regrowth is usually visible 
after 8 to 12 weeks. Treatment must be continued once weekly until complete hair 
regrowth is obtained. Treatment intervals are then decreased, and, eventually 
treatment may be discontinued. However, if relapse occurs, treatment can be restarted 
immediately to stop further progression of AA and to induce renewed hair growth. As 
applicable to many drug therapies, SADBE treatment also has some side effects like 
mild eczematous reactions and enlargement of retroauricular lymph nodes, these are 
usually well tolerated if patients are informed that they are desired for the therapeutic 
effect. Undesired side-effects are noted in 2 to 5% of patients (90). Dissemination of 
allergic contact dermatitis, urticarial or erythema multiforme-like reactions may also 
occur (91), but these can be treated successfully with topical corticosteroids. 
Pigmentary disturbances such as post-inflammatory hyperpigmentation with spotty 
hypopigmentation have been observed, especially in patients with dark skin, but these 
have resolved within 1 year after discontinuing treatment in most instances (92,93). 
Apart from these acute and subacute side-effects, no long-term side-effects have been 
reported after 21 years of SADBE (18 years of DCP) treatment worldwide of about 
10000 patients, including children. However mechanism behind the curative effect is 
still unclear. Several studies point towards the decreased ratio of CD4+:CD8+ T 
lymphocytes with reduction in IFNγ expression elevated IL2, IL10 and TNFα 
expression and also an increase in apoptosis of autoreactive T cells. Recent studies 
have provided a strong evidence of hindrance of APC migration and a strong 
expansion of myeloid derived suppressor cells (MDSC) that suppress T cell 
activation. Till date, SDABE treatment has been proved to be the best treatment for 
AA in human with minimum of side effects. 
 
1.5 Myeloid derived suppressor cells (MDSC) 
 In late 1970’s an unknown population of cell with suppressive features were 
identified. These were named as natural suppressor cells and were first identified in 
bone marrow and spleens of tumor bearing mice which were able to suppress T cell 
responses in vivo and in vitro. Further characterization demonstrated their 
involvement in immune tolerance induction by inhibiting different activities of the 
immune system. These cells were later named as myeloid derived suppressor cells 
(MDSC) since they were involved in regulating myeloid cell differentiation. MDSC 
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represent a heterogenous population of immature myeloid cells that consists of 
myeloid progenitors and precursors of macrophages, granulocytes and dendritic cells 
and are characterized by a strong ability to suppressor various T cell functions 
(Scheme 5). This heterogenticity demonstrates the plasticity of this immune 
suppressive myeloid compartment and shows, how various tumors and infectious 
agent can have similar effects on myeloid cells despite the differences in the factors 
that they produce to influence the immune system (94).  
 
Scheme5. The origin of MDSC: Immature myeloid cells (IMCs) are part of the normal 
process of myelopoiesis, which takes place in the bone marrow and is controlled by a complex 
network of soluble factors that include cytokines such as granulocyte/macrophage colony-stimulating 
factor (GM-CSF), stem-cell factor (SCF), interleukin-3 (IL-3), FMS-related tyrosine kinase 3 (FLT-
3), macrophage colony-stimulating factor (M-CSF) and cell-expressed molecules including Notch 
(not shown). Haematopoietic stem cells (HSCs) differentiate into common myeloid progenitor 
(CMP) cells and then into IMCs. Normally, IMCs migrate to different peripheral organs, where they 
differentiate into dendritic cells, macrophages and/or granulocytes. However, factors produced in the 
tumour microenvironment and/or during acute or chronic infections, trauma or sepsis, promote the 
accumulation of IMCs at these sites, prevent their differentiation and induce their activation. These 
cells exhibit immunosuppressive functions and are therefore known as myeloid-derived suppressor 
cells (MDSC). MDSC can also differentiate into tumor-associated macrophages (TAMs) within the 
tumor environment, which are cells that have a phenotype and function that is distinct from MDSC 
(95). 
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1.5.1 MDSC surface markers and subsets 
 
MDSC are identified as cells that simultaneously express the two markers CD11b and 
Gr-1. More recently MDSC were subdivided into two different subsets based on their 
expression of the two molecules Ly6C and Ly6G. The nuclear morphology and 
content of immunosuppressive substances have also been used to characterize mouse 
MDSC that are mononuclear, are considered “monocytic” and typically are 
CD11b+Ly6G+Ly6Chigh, whereas those with multi-lobed nuclei are 
‘granulocytic/neutrophilic-like’ and have CD11b+Ly6G+Ly6Clow phenotype (96-98). 
Importantly, evidences indicate that these two subpopulations may have different 
functions in cancer, infectious and autoimmune diseases (99-101). The variations in 
MDSC phenotype are consistent with the concept that MDSC are a diverse family of 
cells that are in various intermediate stages of myeloid cell differentiation. Because 
the myeloid population contains many different cell types and myeloid cell 
differentiation is a continuum of processes, MDSC may display diverse phenotypic 
markers that reflect the spectrum of immature to mature myeloid cells (102). This 
diversity prompted the search for markers that could be used to identify such a 
population. Several potential candidates were suggested, such as CD115 (M-CSFR), 
CD124 (IL-4Rα), CD40 and CD80 (103-106), however further studies indicated that 
although these markers are undoubtedly expressed on MDSC, they do not define 
specific immune suppressive populations of MDSC (107).   
In humans, the phenotype of these cells is less clearly defined, although recent studies 
have shown CD15 and CD66b as additional markers allowing for detection of G- 
MDSC and M-MDSC (108,109). These two major subsets of MDSC apparently have 
an important role in the antigen-specific versus non-specific nature of immune 
suppression. G-MDSC, which use reactive oxygen species (ROS) for their 
suppressive functions, require close cell - cell contact with T cells, which in turn is 
manifested by the strong reliance on antigen-specific interaction between MDSC and 
T cells (110). MDSC, which use up-regulation of NO and arginase production of 
immune suppressive cytokines and other mechanisms, effectively suppress antigen-
dependent T cell responses without requiring direct cell-cell contact. Evidence from 
various reports suggests that on a per cell basis M-MDSC are more potent then G-
MDSC (111-114). Experiments demonstrating that treatment with all trans-retinoid 
acid convert MDSC to DCs (115,116) support the concept that MDSC are normal 
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intermediaries. MDSC may play a role in normal homeostasis and maintenance of 
tolerance to self antigens.   
 
1.5.2 MDSC and suppressive activity 
 
MDSC suppress immunity, both innate and adaptive immune responses. Subsequent 
studies showed that the immunosuppressive functions of MDSCs require direct cell– 
cell contact and can be antigen-specific or non-specific, which suggests that they act 
either through cell-surface receptors and/or through the release of short-lived soluble 
mediators (95). Following are the mechanisms by which these cells suppress the 
immune response (Scheme 6): 
 
1.5.2.1 Arginase1 and iNOS: The suppressive activity of MDSCs has been 
associated with the metabolism of L-arginine. L-arginine serves as a substrate for two 
enzymes: iNOS, which generates NO, and arginase1 (ARG1), which converts L-
arginine into urea and L-ornithine. MDSCs express high levels of both arginase and 
iNOS, and a direct role for both of these enzymes in the inhibition of T-cell function 
is well established (117,118). Recent data suggest that there is a close correlation 
between the availability of arginine and the regulation of T-cell proliferation 
(119,120). The increased activity of arginase in MDSC leads to enhanced L-arginine 
catabolism, which depletes this non-essential amino acid from the microenvironment. 
The shortage of L-arginine inhibits T-cell proliferation through several different 
mechanisms, including decreasing their CD3ζ expression (121). In absence of  ζ chain 
CD4+ and CD8+ T cells are unable to transmit the required signals for activation and it 
also prevents the upregulation of the expression of the cell cycle regulators cyclin D3 
and cyclin-dependent kinase 4 (CDK4) (122). Additionally inhibiting the activity of 
arginase and iNOS, which are expressed in malignant but not in normal prostate tissue 
and are key enzymes of L-arginine metabolism, led to decreased tyrosine nitration and 
restoration of T-cell responsiveness to tumor antigens (123). NO suppresses T-cell 
function through a variety of different mechanisms that involve the inhibition of 
JAK3 and STAT5 in T cells , the inhibition of MHC class II expression (124) and the 
induction of T-cell apoptosis (125). 
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1.5.2.2 Reactive oxygen species (ROS): Another important factor that contributes to 
the suppressive activity of MDSC is ROS. Increased production of ROS has emerged 
as one of the main characteristics of MDSC in both tumour-bearing mice and patients 
with cancer (126-130). Inhibition of ROS production by MDSC isolated from mice 
and patients with cancer completely abrogated the suppressive effect of these cells in 
vitro (126,127,129). Interestingly, ligation of integrins expressed on the surface of 
MDSC was shown to contribute to increased ROS production following the 
interaction of MDSC with T cells (126). In addition, several known tumour-derived 
factors, such as TGFβ, IL-10, IL-6, IL-3, platelet-derived growth factor (PDGF) and 
GM-CSF, can induce the production of ROS by MDSC (131).  
 
1.5.2.3. Peroxynitrite: More recently, it has been described that peroxynitrite 
(ONOO-) is a crucial mediator of MDSC-mediated suppression of T-cell function. 
Peroxynitrite is a product of a chemical reaction between NO and superoxide anion 
(O2 -) and is one of the most powerful oxidants produced in the body. It induces the 
nitration and nitrosylation of the amino acids cysteine, methionine, tryptophan and 
tyrosine (132). Increased levels of peroxynitrite are present at sites of MDSC and 
inflammatory-cell accumulation, including sites of ongoing immune reactions. In 
addition, high levels of peroxynitrite are associated with tumor progression in many 
types of cancer (132-135), which has been linked with T-cell unresponsiveness. High 
levels of nitrotyrosine were present in the T cells, which suggested the production of 
peroxynitrites in the tumor environment. In addition, it has been demonstrated that 
peroxynitrite production by MDSC during direct contact with T cells results in 
nitration of the T-cell receptor (TCR) and CD8+ molecules, which alters the specific 
peptide binding of the T cells and renders them unresponsive to antigen-specific 
stimulation. However, the T cells maintained their responsiveness to nonspecific 
stimuli (136). This phenomenon of MDSC induced antigen-specific T-cell 
unresponsiveness was also observed in vivo in tumor-bearing mice (128). 
 
1.5.2.4. Cysteine deprivation: Recent work demonstrates that MDSC also block T 
cell activation by depriving the environment of cysteine, an amino acid that is 
essential for T cell activation. T cells lack the enzyme to convert methionine to 
cysteine and the membrane transporter to import cysteine, which could be reduced 
intracellularly to cysteine, and therefore must obtain their cysteine from extracellular 
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sources. Under healthy conditions, APCs (i.e., DC and macrophages) synthesize 
cysteine from methionine and import extracellular cystine and convert it to cysteine. 
Surplus cysteine is then exported during antigen presentation and imported by T cells. 
MDSC are also unable to convert methionine to cysteine, so they are fully dependent 
on importing cystine for conversion to cysteine. When MDSC are present in high 
concentrations they import most of the available cystine, depriving DC and 
macrophages of cystine. Because MDSC do not export cysteine, their immediate 
environment is cysteine-deficient and T cells are unable to synthesize the necessary 
proteins for activation (102).  
 
Scheme6. Suppressive mechanisms mediated by different subsets of MDSC: 
Myeloid-derived suppressor cells (MDSC) consist of two major subsets: granulocytic MDSC with a 
CD11b+Ly6G+Ly6Clow phenotype and monocytic MDSCs with a CD11b+Ly6G-Ly6Chigh phenotype. In 
most tumour models, it is predominantly (70–80%) the granulocytic subset of MDSC that expands. It 
has been hypothesized that the granulocytic subset of MDSCs has increased activity of STAT3 (signal 
transducer and activator of transcription 3) and NADPH, which results in high levels of reactive 
oxygen species (ROS) but little nitric oxide (NO) production. ROS and, in particular, peroxynitrite (the 
product of a chemical reaction between superoxide and NO) induces post-translational modification of 
T-cell receptors and may cause antigen-specific T-cell unresponsiveness. The monocytic MDSC subset 
has upregulated expression of STAT1 and inducible nitric oxide synthase (iNOS) and increased levels 
NO but little ROS production. NO, which is produced by the metabolism of L-arginine by iNOS, 
suppresses T-cell function through a variety of different mechanisms that involve the inhibition of 
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Janus kinase 3 (JAK3) and STAT5, the inhibition of MHC class II expression and the induction of T-
cell apoptosis. Both subsets have elevated level of arginase-1 (ARG-1) activity that causes T-cell 
suppression through depletion of arginine. Only monocytic MDSCs can differentiate into mature 
dendritic cells and macrophages in vitro (95). 
 
1.5.2.5. Subset-specific suppressive mechanisms: Recent findings indicate that 
different subsets of MDSC might use different mechanisms to suppress T-cell 
proliferation. As already discussed, two main subsets of MDSC have been identified: 
a granulocytic subset and a monocytic subset. The granulocytic subset of MDSC was 
found to express high levels of ROS and low levels of NO, whereas the monocytic 
subset expressed low levels of ROS and high levels of NO and both subsets expressed 
ARG16. Interestingly, both populations suppressed antigen-specific T-cell 
proliferation to an equal extent, despite their different mechanisms of action. The 
suppressive activity of the granulocytic subset was ARG1-dependent, in contrast to 
the STAT1- and iNOS-dependent mechanism of the monocyte fraction (101).  
 
1.5.2.6 Induction of regulatory T cells: MDSC can also promote the development of 
FoxP3+ regulatory T (TReg) cells (137, 138). The induction of TReg cells by MDSC was 
found to require the activation of tumor-specific T cells and the presence of IFNγ and 
IL-10, but was independent of NO (138). In a mouse model of lymphoma, MDSC 
were shown to induce TReg-cell expansion through a mechanism that required arginase 
and the capture, processing and presentation of tumor-associated antigens by MDSC, 
but not TGFβ. In contrast, some other studies suggested that MDSCs were not 
involved in TReg cell expansion since it was found that the percentage of TReg cells 
was invariably high throughout tumor growth and did not relate to the kinetics of 
expansion of the MDSC population (101). Furthermore, in a rat model of kidney 
allograft tolerance that was induced with a CD28-specific antibody, MDSCs that were 
co-expressing CD80 and CD86 were found to have a limited effect on the expansion 
of the TReg cell population (139). Although further work is required to resolve these 
discrepancies it seems possible that MDSCs are involved in TReg-cell differentiation 
through the production of cytokines or direct cell–cell interactions. Furthermore, 
MDSC and TReg cells might be linked in a common immunoregulatory network. 
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1.5.3. Expansion and activation of MDSC 
 MDSC accumulation and expansion are driven by multiple factors which may be 
endogenous or exogenous and can be divided into two main groups. The first group 
includes factors that are produced mainly by tumor cells and promote the expansion 
of MDSC through stimulation of myelopoiesis and inhibiting the differentiation of 
mature myeloid cells. The second group of factors is produced mainly by activated T 
cells and tumor stroma, and is involved in directly activating MDSC (95). 
 
1.5.3.1Granulocyte–macrophage-colony-stimulating factor: Granulocyte 
macrophage colony-stimulating factor (GM-CSF) acts at earlier stages of lineage 
commitment during the steady state regulating the expansion and maturation of early 
hematopoietic progenitors (113, 140). High concentrations of GM-CSF such as 
produced by activated T cells (141), NK-cells and DC (142) during immune responses 
may lead to expansion, redistribution and activation of Gr-1+CD11b+ cells. It has been 
demonstrated that GM-CSF acts differentially on the two MDSC subsets. It expanded 
both, CD11b+Gr-1int and CD11b+Gr-1low subsets in the spleen of tumor-bearing mice, 
but expanded only the CD11b+Gr-1low subset in the bone marrow (143). 
 
1.5.3.2 Vascular endothelial growth factor (VEGF): VEGF and its receptors have 
significant effects in early developmental stages and differentiation of vascular and 
hematopoietic progenitors. Within tumor-associated diseases, VEGF reduces the 
amount of DC and interferes with their function in vivo and in vitro, whereas the 
number of immature precursors of DC increases (144-146). Blocking the activation of 
VEGF receptor was effective at controlling tumor growth and inhibiting the 
infiltration of suppressive immune cells like MDSC, regulatory T cells and 
macrophages, while increasing the mature DC fraction (147). 
 
1.5.3.3 Prostaglandins: Prostaglandins, in particular PGE2, have been widely 
implicated in MDSC-mediated T cell inhibition. In an early study, signaling through 
the PGE2 receptor E-prostanoid (EP) 4 in MDSC was found to induce the expression 
and activity of arginase1. PGE2 promote tumor progression through non-immune 
mechanisms and by limiting anti-tumor immunity through the induction of higher 
levels and more suppressive MDSC (148). 
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1.5.3.4 Interferon-γ: IFNγ is secreted by many cells of the immune system and 
influences functions of T cell and MDSC (149-151). MDSC, in response to 
exogenous or autocrine production of IFNγ, generate ARG1 and iNOS together with 
an autocrine production of IL-13 and induce the expression of IL-4 and IL-13 
receptors (149). It has been shown that MDSC inhibit the cytotoxicity and IFNγ, 
production by NK-cells. After incubation with MDSC, NK-cells could not be 
activated to produce IFNγ, (152). In addition to the cytokines already mentioned, the 
immunosuppressive cytokine transforming growth factor-β (TGF-β) (153-156) as well 
as stem cell factor (SCF) (157), IL-1α, IL-4, IL-6, IL-10, IL-12, IL-13, matrix metallo 
protease-9 (MMP-9), M-CSF and G-CSF seem to have influence on generation and 
function of MDSC (95, 158).  
 
1.5.4 MDSC and signaling 
STAT3 plays a central role in many molecular events governing tumor cell 
proliferation, survival and invasion. At the same time, STAT3 is involved in 
inhibition of anti-tumor immune responses. In myeloid cells, STAT3 signaling drives 
the expression of Bcl-XL, c-myc, cyclin D1 or survivin, which prevents cell 
apoptosis, promotes cell proliferation, and prevents differentiation to mature cell types 
(159). Earlier studies established a crucial role for STAT3 in MDSC expansion in 
mice (160,161). Recently, an association was demonstrated between upregulated 
STAT3 activation and MDSC accumulation in melanoma patients (162). Inhibition of 
STAT3 in vitro abolishes the suppressive activity of MDSC. Ablation of STAT3 
expression in conditional knockout mice or selective STAT3 inhibitors markedly 
reduced the expansion of MDSC and increased T-cell responses in tumour-bearing 
mice (163,164). Abnormal and persistent activation of STAT3 in myeloid progenitors 
prevents their differentiation into mature myeloid cells and thereby promotes MDSC 
expansion. Several pathways downstream of STAT3 might be involved in the 
regulation of MDSC expansion and function. One such pathway involves the calcium-
binding pro-inflammatory proteins S100A9 and S100A8 (165).  In addition, it has 
been shown that MDSC also express receptors for these proteins on their cell surface. 
Activation of STAT3 in hematopoietic progenitor cells (HPC) upregulates S100A8 
and S100A9. This in turn, inhibits DC differentiation and promotes MDSC 
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accumulation (166). The precise mechanism of this effect is not clear, but it was 
suggested that the S100A9 and S100A8 heterodimer participate in the formation of 
the NADPH oxidase (Nox2) complex that is responsible for production of ROS in 
myeloid cells. Increased production of ROS contributes to inhibition of myeloid cell 
differentiation. Upregulation of ROS in MDSC is dependent on increased expression 
of Nox2. STAT3 activation is directly responsible for upregulating transcription of the 
Nox2 components p47phox and gp91phox, increasing ROS production by MDSC in 
tumor-bearing mice (167). PKCbII is required for DC differentiation and is 
downregulated by activated STAT3. STAT3 could also play an indirect role in MDSC 
differentiation. It was shown recently that heat-shock protein 72 (Hsp72), which is 
associated with tumor-derived exosomes, induces suppressive activity of MDSC via 
activation of STAT3. Thus, STAT3 utilizes various molecular mechanisms to regulate 
MDSC expansion and function (166). 
Evidences suggest an important role of STAT1 in regulation of MDSC, STAT1 is the 
main transcription factor activated by IFN-γ or IL-1β signaling and is implicated in 
the regulation of inducible nitric oxide synthase (iNOS) and arginase activity. MDSC 
from STAT1-/- mice failed to up regulate ARG1 and iNOS expression and therefore 
did not inhibit T cell responses (168).  Blocking IFN-γ secretion by T cells also 
abrogates MDSC-mediated suppression, mainly via the block of iNOS upregulation 
(169,170). A recent study demonstrated that STAT1 is particularly important for the 
function of M-MDSCs (171).  
STAT6 activation in MDSCs occurs in response to binding of IL-4 or IL-13 to the 
receptor CD124. This receptor is also described as a MDSC marker and is responsible 
for upregulation of arginase activity and increased TGF-β production by MDSC (172-
175). Other experiments have shown that STAT6 deficiency prevents signalling 
downstream of the IL-4Rα and thereby blocks the production of ARG1 by MDSC 
(163) (Scheme 7). 
 
1.5.4.1. MDSC and Toll like receptors 
In myeloid cells, the toll-like receptor (TLR) family plays a prominent role in NF-kB 
activation, primarily via the myeloid differentiation primary response gene 88 
(MyD88). TLR4 was shown to be involved directly in MDSC function (177), and 
LPS. In combination with IFN-γ, TLR4 could promote MDSC expansion, probably by 
inhibiting differentiation of DC (178). However, wild-type mice and mice lacking a 
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functional TLR4 protein had comparable expansion of the MDSC during 
polymicrobial sepsis, which suggests that signalling through TLR4 is not required for 
MDSC expansion and that MyD88-dependent signalling pathways that are triggered 
by other TLRs probably contribute to the expansion of MDSC in sepsis (179). This 
indicates that the activation of MDSC is a fundamental outcome of the host innate 
immune response to pathogens that express TLR ligands. 
 
Scheme7. Signalling pathways involved in the expansion of MDSC populations:  
The accumulation of myeloid-derived suppressor cells (MDSC) is regulated by several factors that are 
released by tumor cells, tumor stromal cells, activated T cells and macrophages, apoptotic tumor cells, 
bacterial and viral agents and by pathogen-infected cells. These factors trigger several different 
signalling pathways in MDSC that mainly involve the STAT (signal transducer and activator of 
transcription) family of transcription factors. STAT3 regulates the expansion of MDSC by stimulating 
myelopoiesis and inhibiting myeloid-cell differentiation. It also contributes to the increased production 
of reactive oxygen species (ROS) by MDSC. The activation of STAT6 and STAT1, as well as TLR-
mediated activation of nuclear factor-κB (NF-κB), by these factors results in the activation of MDSC, 
which leads to the upregulation of iNOS and arginase and increased production of suppressive 
cytokines such as transforming growth factor-β (TGF-β). In combination with STAT3 they also 
contribute to upregulation of ROS production by these cells. S100A8 and S100A9 directly bind to 
p67phox and p47phox, which are crucial components of NADPH complex. This binding potentiates 
NADPH oxidase activation in MDSC, which causes increased production of ROS, leading to the 
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observed suppressive effects. It is likely that MDSC activation via TLR play especially important role 
during pathogenic infections (95). 
 
It is important to note that an increase in the production and/or recruitment of IMCs in 
the context of acute infectious diseases or following vaccination does not necessarily 
represent an expansion of an immunosuppressive MDSC population. It is likely that 
under pathological conditions, the expansion of a suppressive MDSC population is 
regulated by two different groups of factors that have partially overlapping activity 
firstly, those that induce MDSC expansion and secondly, those that induce their 
activation (which leads to increased levels of ROS, arginase, or NO). This two-tiered 
system may allow for flexibility in the regulation of these cells under physiological 
and pathological conditions. 
 
1.5.5. MDSC and Autoimmunity 
Chronic inflammation and autoimmunity promote MDSC. In experimentally induced 
chronic inflammation of the skin (180), gut (181) and eye (182) an increase in MDSC 
populations is observed. The activation of TLR and the secretion of IL-1α, IL-10 and 
IL-12 are involved in this process (177, 183). In the murine model of multiple 
sclerosis, experimental autoimmune encephalitis (EAE), MDSC accumulate in the 
spleen of immunized mice. Moreover, this subset was capable of suppressing T-cell 
proliferation in vitro (184). There is also evidence suggesting a beneficial role of 
MDSC in autoimmune diseases. A significant increase in the number of MDSC was 
also detected in experimental autoimmune uveoretinitis, an animal model of human 
intraocular inflammatory disease (185) and in the skin and spleens (180) of mice that 
were repeatedly treated with a contact sensitizer to induce an inflammatory skin 
response and in inflammatory bowel diseases (186). MDSC were also found to 
infiltrate the spleen and suppress T-cell function in a model of traumatic stress (187). 
With the aim to find a possible therapy for alopecia areata, mice were persistently 
stimulated on the skin with a contact sensitizer in order to give rise to a chronic 
eczema that is accompanied by the generation and recruitment of MDSC, which, in 
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1.6 Alopecia areata and adhesion molecules  
In AA, as discussed before there is an infiltration of leukocytes at the site of disease. 
Since, adhesion molecules like CD44 or integrins play an important role in leukocyte 
extravasation and homing, it becomes important to discuss about the significance of 
adhesion molecule with AA. 
Adhesion molecules are important in inflammatory responses and may have roles in 
directing autoimmune processes through their expression on lymphoid and non-
lymphoid tissues. Interaction of adhesion molecules with their ligands mediate 
adherence of leukocytes to other cells and also to extracellular matrix. Adhesion 
molecule regulates leukocytes circulation, lymphoid cell homing to tissue and 
inflammatory sites and transendothelial migration and also participates in lymphocyte 
co-stimulation, cytotoxicity, lympho-haemopoiesis and leukocyte apoptosis. Adhesion 
molecules relevant to leukocytes have been classified as; 
 Selectins: selectins are expressed on leukocytes, platelets and endothelial cells. Their 
common structural component is an N terminal lectin binding domain. Selectins have 
been further classified as L-selectin (Lymphocytes), P-selectin (Platelets), E selectins 
(Endothelium). Selectin binding and rapid association and disassociation to 
glycosylated and sialyated ligands mediate leukocyte rolling along the endothelial cell 
wall and are involved in initial localization of leukocytes to inflammatory sites. 
Rolling of leukocyte at inflammatory sites exposes them to chemo-attractants and 
cytokines. This exposure leads to leukocytes activation, upregulation of additional 
adhesion molecules, chemotaxis and prolonged localization of cells to a site of 
inflammation (188). 
 Immunoglobulin super family (IGSF): are named and classified together because 
each receptor has immunoglobulin like amino-acid domain. The IGSF includes 
several related cell surface proteins found on immunocompetent cells like CD4, CD8, 
T cell receptor/CD3 complex and MHC classI and Class II molecules. IGSF receptors 
functioning as adhesion molecule which include “lymphocytes function antigen” 
(LFA-2, CD2 and LFA-3), intracellular adhesion molecules (ICAM-1 and ICAM-2) 
and VCAM-1. ICAM-1 and VCAM-1 are principal receptors of LFA-1 and VLA-4 
respectively. Cytokine stimulation of endothelial cells increased ICAM-1 expression, 
which promotes adherence of LFA-1 positive leukocytes to inflammatory sites. VLA-
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4/VCAM-1 adhesion may be primarily responsible for prolonged cell adhesion at 
inflammatory sites (189). 
 Integrin: Integrin adhesion molecules are heterodimeric proteins composed of non- 
covalently bound α and β subunits. Subunit combinations form functionally different 
receptors. Each contains a large extracellular domain, a transmembrane domain, and a 
generally short cytoplasmic tail. The extracellular domains of integrins bind ligands in 
the extracellular matrix (ECM) like fibronectin, vitronectin, laminin, collagen etc. or 
on the surface of other cell types to mediate either cell-substratum or cell-cell 
adhesion. In addition to forming these physical connections, integrins regulate cell 
signaling pathways through their cytoplasmic domains. These signaling pathways are 
important in coordinating cell migration. In particular, the α4β1 integrin (CD49d) 
mediates leukocyte migration essential for immune surveillance and inflammation. An 
ECM binding motif for many integrins is the amino acid sequence “arginine-lysine-
aspartate” (RGD) domain. Fibronectin, vitronectin and other integrins binding extra-
cellular proteins have this RGD domain (190). 
   It has been shown that α4 integrin (CD49d) associates with CD44 and contributes to   
leukocyte extravasation. Lymph node cells of AA mice displayed increased motility, 
proliferative activity and apoptosis resistance, which were equally inhibited by both 
CD44- and CD49d-specific antibodies (191). 
 
1.7 CD44 
The CD44 proteins form a rather ubiquitously expressed family of cell surface 
adhesion molecules involved in cell-cell and cell-matrix interactions. The CD44 
glycoproteins are well characterized members of the hyaluronate receptor family of 
cell adhesion molecules (192,198). CD44 has been described into a multitude of 
functions. The major physiological role is to maintain organ and tissue structure via 
cell-cell and cell-matrix adhesion. In leukocytes it has been characterized as an 
adhesion receptor engaged by migrating T cells including leukocyte extravasation. It 
also mediates T cell activation and thymic homing.  
 
1.7.1 CD44 structure 
1.7.1.1 Gene structure: The human CD44 gene has been mapped to the chromosomal 
locus 11p13 (192). CD44 glycoproteins are encoded by a single gene. They vary in 
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size owing to N-glycosylation and O-glycosylation and the insertion of alternatively 
spliced exon products in the extracellular domain of the molecule. The smallest 
standard or hematopoietic isoform (CD44s) is present on the membrane of most 
vertebrate cells. CD44 has seven extracellular domains, a transmembrane domain and 
a cytoplasmic domain (193). The standard CD44 consist of consists of an N-terminal 
signal sequence (exon 1), a Link-homology hyaluronan-binding module (exons 2 and 
3), a stem region (exons 4, 5, 16 and 17), a single-pass transmembrane domain (exon 
18) and a cytoplasmic domain (exon 20). Alternative splicing of CD44 predominantly 
involves variable insertion of different combinations of exons 6-15 (variant exons v1-
v10) into the stem region. Nearly all CD44 cDNAs isolated have exon 19 spliced out, 
producing an open reading frame encoding a 73 amino acid cytoplasmic domain. The 
inclusion of exon 19 would generate a short 5 amino acid cytoplasmic tail terminating 


















Scheme8. Gene structure of CD44 (195) 
 
1.7.1.2 Protein structure: The most abundant standard isoform of human CD44 
protein (CD44s) contains 363 amino acid (aa) and has a theoretical molecular mass of 
37 kDa. The protein consists of three regions, 270 amino acid (aa) extracellular 
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domain, 21 aa transmembrane domain and 72 aa C-terminal cytoplasmic domain. The 
highly conserved cytoplasmic tail can exist as a short or a more prevalent long form 
by the inclusion of the C-terminal exon (196). The hydrophobic transmembrane 
domain is encoded by exon 18 and is 100% conserved between mammalian species. 
The extracellular domain can be subdivided further into conserved and non-conserved 
regions. The N-terminal ectodomain, encoded by exons 1 to 5 is highly conserved (~ 
85%) between mammalian species and is thought to fold into a globular tertiary 
structure by the formation of disulphide bonds between three pairs of cysteine 
residues. Also present in this part of the molecule is a 100 aa region of homology with 
other hyaluronic acid (HA) binding proteins. This is termed the “link module” or CLP 
domain because of its resemblance to the HA binding domain of cartilage link protein 
(197). The variable region is the point at which up to 381 aa encoded by the 10 
alternatively spliced variant exons are inserted at a site between exons 5 and 16 of the 
RNA transcript, corresponding to amino acid position 223. The membrane proximal 
region of the extracellular domain, encoded by exons 16 and 17 is less conserved 
(35%) between mammalian species and includes several carbohydrate modification 













Scheme9. CD44 protein structure: The standard form binds its principal ligand, hyaluronic acid at 
the N-terminal, distal extracellular domain. The inclusion of combinations of the variant exons (v1-v10) within the 
extracellular domain can alter the binding affinity for hyaluronic acid and confer interaction with alternative 
ligands. The molecule interacts with the cytoskeleton through the binding of ankyrin and the ERM family to the 
cytoplasmic domain (192) 
 
                                                                                                                      Introduction 
 35
 
1.7.1.3 Post-translational modifications: The apparent molecular mass of the CD44s 
protein, as estimated by gel electrophoresis, is ~80 kDa and the largest possible 
protein, containing peptides from all variant exons (referred to as “epican”) can be 
over 200 kDa which is much greater than the expected value as calculated from aa 
residues and is due to the extensive post-translational modification of CD44 isoforms 
(192). In cultured cells, CD44 is constitutively phosphorylated at Ser325 in the 
cytoplasmic tail (199-201). Ser325 phosphorylation is estimated to occur on ~25-40% 
of CD44 molecules and is mediated by Ca2+/calmodulin-dependent protein kinase II 
(CaMKII). Phosphorylation at Ser325 and Ser291 residues has been implicated in 
mediating cell migration on HA and in the interaction of CD44 with ezrin. Mutations 
at Ser325 site impair hyaluronan-mediated cell migration (202).   
 
1.7.1.4 Palmitoylation: CD44 is reversibly palmitoylated (203,204), the prospective 
acylation sites being Cys286 and/or Cys295. In the case of CD44, acylation has been 
reported to impair anti-CD3 mediated signal transduction in lymphocytes (204) and 
enhance the association of CD44 with ankyrin. (203). Given the location of these 
cysteine residues in the CD44 sequence, palmitoylation might also play a role in 
partitioning CD44 into membrane subdomains and/or in regulating its association 
with ERM proteins. 
 
1.7.1.5 Modification by proteolytic processing: It has been described that the 
extracellular domain of CD44 is subject to regulated proteolytic cleavage (205). 
Membrane type1 (MT1)-MMP and MT3-MMP has been shown to release soluble 
CD44 (206,207). CD44 cleavage can generate two cell associated CD44 species (~25 
kDa and ~12 kDa) in addition to the secreted extracellular domain fragment (208-
211). The ~25 kDa species corresponds to the residual membrane-bound C-terminal 
fragment (CTF), whereas the major product isolated from the ~12 kDa band is a 
CD44 intracellular domain (ICD) fragment resulting from a cleavage just inside the 
CD44 transmembrane domain.The released CD44-ICD fragment translocates to the 
nucleus and stimulates transcription, one of its target genes is the gene encoding 
CD44 itself (211).  
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1.7.2 CD44 Functions 
CD44 proteins have essential functions in life and their dysfunction, absence or over 
expression can lead to pathogenic phenotype. It has been described that CD44 null 
mice were viable and had relatively mild phenotype. Interestingly activated T cells 
survived longer in null mice than wild type mice which led to a resistance to hepatitis 
that could be explained by the involvement of CD44 in proapoptotic signaling (213). 
The multiple functions of the CD44 family of proteins are centered around the 
binding of HA and, to a lesser extent, other extracellular molecules. A transmembrane 
domain and a minimal cytoplasmic domain are required for efficient ligand binding 
(214,215), probably stabilizing CD44 at the plasma membrane and promoting 
receptor clustering. 
 
1.7.2.1 Cell adhesion and migration 
Cell adhesion and migration are critical steps in cancer progression and inflammatory 
responses and cell migration is important for tissue remodeling, wound healing and 
leukocyte migration. The CD44 dependent adhesion mechanism is most important for 
mobilization of effector cells at sites of infection and inflammation. Adhesion of 
CD44 to its ligand(s) induces up-regulation of additional adhesion molecules, mostly 
integrins like CD49d that strengthen adhesion. It has been suggested that CD44 and 
CD49d comes into proximity during T cell activation. On activated T cells, CD44 can 
regulate tethering and rolling interactions with vascular endothelial cells that express 
HA (216). The affinity of CD44 for HA seems to be modulated from inside the cells, 
as its binding affinity is upregulated by mitogenic stimuli, influenced by glycosylation 
of the extracellular domains and also by the phoshphorylation of specific serine 
residues in the cytoplasmic domain of CD44 (217), deletion of the cytoplasmic tail of 
CD44 prevents firm adhesion of cells to endothelium, which follows rolling as the 
first step in leukocyte extravasaation (218). There has been evidence for the 
physiological importance of the involvement of CD44s in leukocyte extravasation. It 
has been described that the development of an  oedema and leukocyte immigration 
into inflamed tissue as in delayed type hypersensitivity reactions can be strongly 
inhibited by anti-pan CD44 (219-221). In addition to the well defined role of CD44 in 
extravasation of T cells, CD44 also plays a crucial role in regulating cell motility 
within the tissue stroma. In tissue resident T cells CD44 and other adhesion receptors 
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localizes to the leading edges and lamellopodia (222). Intracellular signals not only 
guide CD44 to the leading edge but also support CD44 mediated cell motility by 
cleavage of extracellular domain by membrane type metalloproteinases 1 (MT1-
MMP) (209,223). 
1.7.2.2 Interaction with the cytoskeleton  
The cytoskeleton is a highly dynamic structure that reorganizes when cells respond to 
extracellular stimuli via actin polymerization and the rearrangement of the underlying 
cortical actin filaments (199-201). 
CD44 cytoplasmic domain lacks a binding site for actin. Therefore it mediates the 
interaction with actin via adaptor proteins like ankyrin, ERM family of proteins 
(ezrin, radixin and moesin) and related protein merlin (202). An ankyrin binding 
domain has been identified (203) and binding is influenced by many factors including 
palmitoylation (204). PKC mediated phosphorylation and GTP binding. Ankyrin 
binding is important for HA binding and cell adhesion as deletion of the ankyrin 
binding domain results in nearly complete loss of HA binding (227). 
ERM proteins act as key linkers between transmembrane proteins and cytoskeleton.  
The ERM proteins have a 300 amino acid domain at the N-terminus, α-helical central 
region and a C-terminal domain which has the F-actin binding site. ERM proteins are 
activated by phosphorylation and by binding to membrane phospholipids. It is the 
phoshorylated (active) form of ERM that binds to CD44 (202). ERM activation is 
regulated via Rho GTPase family. Binding of ROK, PKC and phosphatidyl inositol 4, 
5 bisphosphate (PIP2) to ERM proteins results in phosphorylation of these proteins 
(228-230). Thr567 Ezrin, Thr564 Radixin and Thr558 Moesin phosphorylations result in 
rearrangement of the cytoskeleton (231). CD44 binding to the cytoskeleton is further 
regulated by its cytoplasmic domain. In resting cells CD44 is phosphorylated at 
Ser325. The switch from Ser325 phosphorylation to Ser291 is triggered via PKC and 
leads to a break in the association between ezrin and CD44 (Scheme 10). In addition, 
Ser291 phosphorylation is also involved in directional migration of cells. Merlin 
protein has 65% homology to ERM proteins. Its activity is also regulated through 
phosphorylation and dephosphorylation (232). Merlin does not have an actin binding 
site and merlin-CD44 complex cannot bind to cytoskeleton (233). The ability of 
ERM/merlin proteins to switch between phosphorylated and dephosphorylated forms 
along with the competition between ERM and merlin to bind to CD44 leads to making 
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and breaking of CD44 interactions with the cytoskeleton [234]. Merlin is inactivated 
after its phosphorylation and prohibits its binding to CD44 When cells are in the 
growth phase, phosphorylated ERM binds to CD44 mediating cytoskeletal 
interactions. During this time merlin gets phosphorylated by PAK2 (p21-active kinase 
-2) and is now unable to bind to CD44. During growth arrest the opposite mechanism 
is under rule and MAPK activation is blocked (235, 236). 
 
 
Scheme10. Model for the regulation of the CD44-ERM complex by dynamic 
phosphorylation of the CD44 cytoplasmic tail: The ERM (ezrin, radixin, moesin)-family 
proteins can function to crosslink transmembrane receptors, including CD44, to the cytoskeleton. Their basic 
structure consists of the three-lobed N-terminal FERM domain followed by a coiled-coil region and a C-terminal 
domain that contains an F-actin binding site. In their ‘inactive’ conformation, the C-terminal domain binds to the 
FERM domain, masking both transmembrane receptors and F-actin interaction sites. Conformational regulation 
between the ‘inactive’ and ‘active’ forms involves complex mechanisms including phosphorylation and binding to 
the membrane phospholipids phosphatidylinositol 4,5-bisphosphate (PIP2). The cytoplasmic tail of CD44 is 
phosphorylated at Ser325 by CaMKII and this form of the receptor binds to an ‘active’ ERM protein that links 
CD44 to the actin cytoskeleton. PKC activation results in a concomitant dephosphorylation of Ser325 and 
phosphorylation of Ser291, resulting in disengagement of the ERM proteins and loss of cytoskeletal association 
(212). 
 
1.7.2.3 Role in lymphocytic function 
Several lymphocyte functions appear to be dependent upon CD44 expression. 
Increased surface levels of CD44 proteins are characteristic of T cell activation after 
encounter with its cognate antigen (238). Cell surface CD44 on lymphocytes can 
mediate the adhesion of lymphocytes to vascular endothelial cells via binding of HA, 
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and this interaction is used for activated T cell extravasation into sites of 
inflammation in mice (239) and in humans (240). This targeting of lymphocytes to 
effector sites by CD44–HA binding is enhanced by the induction of HA synthesis in 
vascular endothelium by the proinflammatory cytokines, TNF-α and IL-1α (241). 
Accordingly, the presence of CD44 splice variants appears to be obligatory for the 
migration and function of Langerhans cells and dendritic cells from peripheral organs 
to lymph nodes for antigen presentation (242). CD44 has a role in mediating the 
functions of regulatory T cell as well, which are essential for the prevention of 
autoimmunity. CD44 deficient Tregs fail to persist after transfer in vivo. The in vitro 
ligation of CD44 on activated wild type Tregs promotes persistent expression of the 
transcription factor FoxP3, which is essential for regulatory activities. These functions 
of CD44 are shown to be dependent upon the interaction with high molecular weight 
forms of HA that are found in the absence of inflammatory responses. 
 
1.7.2.4 CD44 signaling 
The location of CD44 in GEMs is of particular importance with respect to CD44 
mediated signal transduction, as the inner side of these microdomains is known to 
harbor signal transducing molecules. CD44 signaling can result in opposing effects 
depending on the cellular context, the expressed variant isoform and the associated 
signaling partner, for example, CD44 engagement can lead to proliferation or 
inhibition of proliferation, apoptosis or inhibition of apoptosis, resulting in up-
regulation and down-regulation of several signaling pathways involved in cell 
activation. 
However CD44 lacks intrinsic catalytic activity and its signaling depends upon its 
association with receptor tyrosine kinases and the Src family of phosphotyrosine 
kinases (PTKs). Src kinases act as molecular switches on the cell membranes linking 
extracellular events to intracellular signaling. They are activated through engagement 
with many receptors such as TCR/CD3 complex, CD4, CD8, B cell receptor, Fc 
receptors, integrins, GPI anchored receptors and growth factor receptors (193). When 
activated they mediate several signaling events including activation of additional 
PTKs such as ZAP-70 or Syk, phospholipases, cytoskeletal proteins and adaptor 
proteins. CD44 and the associated lck are recruited into membrane microdomains 
where they interact with the CD3/TCR complex. Association of CD44 with lck and 
fyn and in turn their co-localisation with the TCR allow for recruitment of several 
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other kinases necessary for T cell activation (243, 244).  The co-stimulatory function 
of CD44 is demonstrated by its ability to induce cell proliferation on freshly isolated 
lymph node cells in the presence of sub-threshold levels of anti-CD3. This is mediated 
by activation of several tyrosine kinases and is accompanied by strong activation of 
ERK and c-jun and involvement of MAPK (Scheme 11). Consequently, IL-2 
production and CD69 and CD25 expression are up-regulated in T cells. The situation 
differs in a T helper line (IP-12) where it was observed that CD44-cross-linking with 
CD3 leads to upregulation of CD95 and CD95L expression resulting in apoptosis 
induction (or activation induced cell death AICD). This argues for differential effects 
of CD44 on different cell types. It is important to note that, in both peripheral T cells 
and a T helper line, CD44 cross linking alone did not exert any effect on signaling by 
itself. This is in line with two signals one from the TCR and the other from a co-
stimulatory molecule. In antigen-specific T cell activation, CD44 has been described 
to deliver co-stimulatory signals for T cell activation (243). 
CD44 mediated cytoskeletal reorganization appear to be dependent on Rac1 
activation. Small GTPase Rac1 activation is required for this process. Rac1 is also 
known to co-localise with ezrin (245). These events along with phosphotyrosine 
kinase activations are responsible for cytoskeletal re-organizations in the cell. In T 
lymphocytes cross-linking anti-CD44 Ab leads to CD44-dependent spreading through 
F-actin polymerization, accompanied by T cell adhesion, flattening and spreading 
(244). Vav1 protein encoded by vav proto-oncogene is a 95 kD protein that is an 
upstream regulator of Rac1. Vav catalyses the GDP to GTP exchange on Rac1. Vav1 
activation involves phosphoinositides binding and tyrosine phosphorylation that is 
dependent on Src family kinases (lck and fyn) which associate with CD44. Thus, this 
could be a possible explanation for CD44 mediated effects on the cytoskeleton (244, 
246,247). Another mediator of CD44 signalling is RhoA and its downstream effector 
Rho-Kinase (ROK). ROK phosphorylates the cytoplasmic domain of CD44v3 which 
strengthen the interaction between these and ankyrin and supports tumor cell 
migration. In endothelial cells, migration is stimulated after CD44v10–HA binding by 
interaction between ROK and CD44v10 (248). 
Some studies have shown that CD44 is capable of activating human resting T cells 
and mouse cytotoxic T cells by itself and can promote proliferation of T cells that is 
dependent on IL-2 provision. In this study, anti-CD44 cross-linking does not 
phosphorylate the ξ chain of the TCR complex indicating that the signals generated in 
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this case are independent of TCR engagement. Indeed, it was demonstrated that this 
process is mediated by tyrosine kinases associated with CD44 (249).  
Using a mouse model for the autoimmune disease alopecia areata Marhaba et al., have 
shown an association between CD44 and CD49d. This association resulted in the 
formation of a signaling complex between CD44, CD49d and the underlying signaling 
machinery allowing for each surface molecule (CD44 or CD49d) to avail from the 
associated signaling molecules of the other. In this case, cross-linking of CD44 
resulted in the activation of the focal adhesion kinase (FAK) associated with CD49d, 
and CD49d cross-linking allowed the activation of Ezrin and Lck associated with 
CD44. Thus signaling pathways initiated through both the molecules CD44 and 
CD49d are triggered which could well be important in lymphocyte activation and 
function (191). 
 
Scheme11.   CD44 and signaling (250). 
 
1.7.2.5 CD44 and Alopecia areata 
The involvement of CD44 in autoimmune diseases is well known. As it has been 
already discussed above, AA is most effectively cured by the induction of DTH via 
chronic contact eczema treatment by SADBE. One of the mechanisms behind is 
expansion and activation of MDSCs and another aspect which is important in the cure 
of AA by chronic contact eczema is that there should be an impaired T cell activation 
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as a result of hindrance in APC migration towards draining lymph node. CD44 is 
described as lymphocyte homing receptor and plays a major role in leukocyte 
extravasation. In autoimmune diseases and allergic reactions, there are several reports 
suggesting alterations in the intensity of CD44 expression as well as changes in the 
pattern of CD44 and variant isoforms in autoimmune diseases. It has been shown that 
both CD44 and isoforms are supposed to function as costimulatory molecules (251-
253). Induction of AA in mice can be prevented by repeated injections of CD44v10. 
The blockade of CD44 on endothelial cell can contribute to the inhibition of  
leukocyte extravasation, but the different efficacy of an anti-CD44 blockade in 
diseased as compared with healthy mice depends upon leukocytes. The anti-CD44 
mediated inhibition of T cell extravasation preferentially affected activated 
(CD69+CD154+) T cells. T cell migration is more strongly inhibited with anti-
panCD44 than anti-CD44v10. Instead macrophage recruitment was more affected by 
anti-CD44v10 (254). Another important role of CD44 in leukocyte rolling and firm 
adhesion to vessel endothelium is due to its association with CD49d. Since 
autoimmune diseases are reflected by an increased percentage of peripheral blood 
leukocytes expressing activated CD44, it became relevant to look for the CD44 and 
CD49d association. This wide range of CD44 activities leads to a speculation that 
association of CD44 with CD49d could play an important role in leukocyte activation 
and /or apotosis resistance. In additionan antibody blockade of different CD44 
isoforms may provide therapeutics in T cell mediated autoimmune disease like 
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1.8 Aims of the study 
Alopecia areata (AA) is an organ related autoimmune disease that is cured most 
efficiently by chronic contact eczema. However, the underlying mechanism is 
unknown. To unravel the mechanism I aimed to shed some more light on the mode of 
T cell activation in Alopecia areata and the mechanisms promoting the therapeutic 
efficacy of chronic contact eczema, I approached to the following questions: 
  
1. Do adhesion molecules, particularly CD44 and CD49d account for T cell 
expansion and hyperactivity in Alopecia areata: This work builds on 
previous studies in our lab which showed that in T cells from Alopecia areata, 
but not of healthy mice, CD44 associates with CD49d. This associatrion 
support T cell migration, proliferation and apoptosis resistance. To prove that 
the CD44-CD49d association is essential for the observed effects, I generated 
T cell lines expressing either mutated CD44 or mutated CD49d. The T cell 
lines differed, in addition, by CD3/TCR expression. This allowed to 
concomitantly attend the question of a TCR-dependant versus TCR-
independent modulation of T cell activity via adhesion molecules. 
 
2. Are myeloid derived suppressor cells (MDSC), the driving force in the 
SADBE-induced cure of Alopecia areata: Myeloid derived suppressor cells 
have been found to be expanded in SADBE-treated Alopecia areata (AA) 
mice. However, studies were still missing to demonstrate their essential 
contribution to the therapy of Alopecia areata. I approached this question by a 
direct comparison of ex-vivo analyzed leukocytes from AA and SADBE-
treated AA mice with co-cultures of AA T cells with separated MDSC. In 
addition, I started to unravel the molecular pathways, whereby MDSC derived 
from SADBE-treated AA mice affect autoreactive T cells.
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C3H/HeJ Jackson Laboratories, Bar Harbour, USA 
 
2.1.2 Bacterial strain 
E.coli DH5α       Genotype: F-, Φ80dlacZ∆M15, ∆(lacZYA-
argF)U169, deoR, recA1, endA1, hsdR17(rk-
,mk+), phoA, supE44, thi-1, gyrA96, rel A1, λ- 
(Invitrogen, Darmstadt, Germany) 
2.1.3 Cell Lines 
Cell Line Origin 
EL-4 
 
Mouse Thymoma, American Type Culture 
Collection (ATCC) number: TIB- 39 
EL4+wtCD49d  EL4 cells transfected with mouse wild type CD49d 
EL4+mutCD49d  EL4 cells transfected with mouse CD49d muataed 
at Ser988 to alanine 
Jurkat  Human T lymphocyte ATCC TIB-152 
Jurkat+wtCD44  Jurkat cells transfected with mouse wild type CD44 
Jurkat+mutCD44  Jurkat cells transfected with mouse CD44 mutated 
at Ser291 and Ser325 to alanine 
Jurkat+truncCD44  Jurkat cells transfected with mouse CD44 excluding 
cytoplasmic tail 




F   5’-GCAGTGAATTCCCACCATGGACAAGGTTTGGTGGCAC -3’ 
mouseCD44wt 
R  5’-CGACGCTCGAGCACCCCAATCTTCATATCCAC -3’ 
F  5’-CATTTCCTGAGACTTGGCGGCCTCCCCGTTGGGGTACCCC -3’mouseCD44mut 
ser291 R  5’-GGGTACCCCAACGGGGAGGCCGCCAAGTCTCAGGAAATG-3’
F   5’-GTCTGCATCGCGGTCAATGCTAGGAGAAAGG -3’ mouseCD44mut 
ser325 R  5’-CTGCCCACACCTTCTCCTAGCATTGACGGCGATCCACAG -3’ 
F   5’- GCAGTGAATTCCCACCATGGACAAGGTTTGGTGGCAC -3’ mouseCD44-
truncated R  5’- TAGTCTAGAACTATTGACCGCGATGCA-3’ 
F   5’-GAGAATTCATGGCTGCGGAAGCGAG-3’ 
mouseCD49d  R  5’-CGCTCGAGTCAGTCATCATTGCTTTTGC-3’ 
F 5’-CGACGCGTATTATTACCATCGCCTTGCTACTTGG-3’ mouseCD49d mut 
ser298 R  5’-CGACGCGTCCAAGTAGCAAGGCGATGGTAATAAT-3’ 
 
2.1.5 Primary Antibodies 
Antibody Company  
Anti-Actin Becton Dickinson, Heidelberg, Germany 
Anti-akt Becton Dickinson, Heidelberg, Germany 
Anti-BAD Becton Dickinson, Heidelberg, Germany 
Anti-Bax Becton Dickinson, Heidelberg, Germany 
Anti-Bcl2 Becton Dickinson, Heidelberg, Germany 
Anti-Caspase 3 Becton Dickinson, Heidelberg, Germany 
Anti-Caspase 8 Becton Dickinson, Heidelberg, Germany 
Anti-Caspase 9 Becton Dickinson, Heidelberg, Germany 
Anti-Caspase 9 cleaved Cell Signalling, Frankfurt , Germany 
Anti-CD1d Becton Dickinson, Heidelberg, Germany 
Anti-CD3ζ Abcam Cambridge UK 
Anti-CD4 (YTA) European Animal Cell Culture collection, UK 
Anti-CD8 (YTS169) European Animal Cell Culture collection, UK 
Anti-CD11b (YBM) European Animal Cell Culture collection, UK 
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Anti-CD11c Becton Dickinson, Heidelberg, Germany 
Anti-CD16/32 Becton Dickinson, Heidelberg, Germany 
Anti-CD18 Becton Dickinson, Heidelberg, Germany 
Anti-CD25 Becton Dickinson, Heidelberg, Germany 
Anti-CD28 Becton Dickinson, Heidelberg, Germany 
Anti-CD40 Becton Dickinson, Heidelberg, Germany 
Anti-CD44(IM7) American type culture collection 
Anti-CD44 Becton Dickinson, Heidelberg, Germany 
Anti-CD49a Becton Dickinson, Heidelberg, Germany 
Anti-CD49b Becton Dickinson, Heidelberg, Germany 
Anti-CD49c Becton Dickinson, Heidelberg, Germany 
Anti-CD49d Becton Dickinson, Heidelberg, Germany 
Anti-CD49d (PS/2) American type culture collection 
Anti-CD49f Becton Dickinson, Heidelberg, Germany 
Anti-CD50 Becton Dickinson, Heidelberg, Germany 
Anti-CD54 (YN1/1.7.4) American type culture collection 
Anti-CD54 Becton Dickinson, Heidelberg, Germany 
Anti-CD62E Becton Dickinson, Heidelberg, Germany 
Anti-CD62L Immunotools, , Friesoythe; Germany 
Anti-CD62L-lig Becton Dickinson, Heidelberg, Germany 
Anti-CD62P Becton Dickinson, Heidelberg, Germany 
Anti-CD69 Becton Dickinson, Heidelberg, Germany 
Anti-CD80 Becton Dickinson, Heidelberg, Germany 
Anti-CD86 Becton Dickinson, Heidelberg, Germany 
Anti-CD95 Becton Dickinson, Heidelberg, Germany 
Anti-CD95l Becton Dickinson, Heidelberg, Germany 
Anti-CD102 Becton Dickinson, Heidelberg, Germany 
Anti-CD106 Becton Dickinson, Heidelberg, Germany 
Anti-CD120a Becton Dickinson, Heidelberg, Germany 
Anti-CD120b Becton Dickinson, Heidelberg, Germany 
Anti-CD152 Becton Dickinson, Heidelberg, Germany 
Anti-CD154 Becton Dickinson, Heidelberg, Germany 
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Anti-CD253 Biozol Eching, Germany 
Anti-CD254 Becton Dickinson, Heidelberg, Germany 
Anti-CD265 Becton Dickinson, Heidelberg, Germany 
Anti-CD284 Biolegend,  Uithoorn, Netherlands 
Anti-c-jun Santa Cruz, Heidelberg, Germany 
Anti-cytochrome c Becton Dickinson, Heidelberg, Germany 
Anti-ERK1/2 Becton Dickinson, Heidelberg, Germany 
Anti-Ezrin Becton Dickinson, Heidelberg, Germany 
Anti-FAK Becton Dickinson, Heidelberg, Germany 
Anti-FoxP3 Becton Dickinson, Heidelberg, Germany 
Anti-Gr1 Becton Dickinson, Heidelberg, Germany 
Anti- IFNγ Becton Dickinson, Heidelberg, Germany 
Anti-IL-1α Becton Dickinson, Heidelberg, Germany 
Anti-IL-10 Becton Dickinson, Heidelberg, Germany 
Anti-IL-12 Becton Dickinson, Heidelberg, Germany 
Anti-IL-2 Becton Dickinson, Heidelberg, Germany 
Anti-IL-4 Becton Dickinson, Heidelberg, Germany 
Anti-IL-6 Becton Dickinson, Heidelberg, Germany 
Anti-iNOS Becton Dickinson, Heidelberg, Germany 
Anti-JNK Becton Dickinson, Heidelberg, Germany 
Anti-LAT Santa Cruz, Heidelberg, Germany 
Anti-Lck Santa Cruz, Heidelberg, Germany 
Anti-Ly6C Becton Dickinson, Heidelberg, Germany 
Anti-LY6G Becton Dickinson, Heidelberg, Germany 
Anti-NFkB Santa Cruz, Heidelberg, Germany 
Anti-pAkt Becton Dickinson, Heidelberg, Germany 
Anti-Paxillin Becton Dickinson, Heidelberg, Germany 
Anti-pBAD Cell Signalling, Frankfurt , Germany 
Anti-p-c-jun Santa Cruz, Heidelberg, Germany 
Anti-pERK1/2 Santa cruz, Heidelberg, Germany  
Anti-pI3K Santa Cruz, Heidelberg, Germany 
Anti-pJNK Becton Dickinson, Heidelberg, Germany 
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Anti-pLck Santa Cruz, Heidelberg, Germany 
Anti-pZAP70 Becton Dickinson, Heidelberg, Germany 
Anti-Smac Becton Dickinson, Heidelberg, Germany 
Anti-Stat3 Becton Dickinson, Heidelberg, Germany 
Anti-Stat6 Becton Dickinson, Heidelberg, Germany 
Anti-TNFRI Becton Dickinson, Heidelberg, Germany 
Anti-TNFRII Becton Dickinson, Heidelberg, Germany 
Anti-TNFα Becton Dickinson, Heidelberg, Germany 
Anti-Trail Becton Dickinson, Heidelberg, Germany 
Anti-ZAP70 Becton Dickinson, Heidelberg, Germany 
2.1.6 Secondary antibodies 
Name Company 
Anti-mouse IgG HRP Amersham, Freiburg, Germany 
Anti-rabbit IgG HRP Amersham, Freiburg, Germany 
Anti-rat IgG HRP Amersham, Freiburg, Germany 
Anti-mouse IgG PE Jackson Laboratories, Bar Harbor,USA 
Anti-hamster IgG FITC Jackson Laboratories, Bar Harbor,USA 
Anti-mouse IgG FITC Jackson Laboratories, Bar Harbor,USA 
Anti-mouse IgG APC Jackson Laboratories, Bar Harbor,USA 
Anti-rat IgG FITC Jackson Laboratories, Bar Harbor,USA 
Anti-rat IgG PE Jackson Laboratories, Bar Harbor,USA 
Anti-rat IgG APC Becton Dickinson  Heidelberg, Germany 
Streptavidin FITC Jackson Laboratories, Bar Harbor,USA 
Streptavidin PE Jackson Laboratories, Bar Harbor,USA 
Streptavidin APC Jackson Laboratories, Bar Harbor,USA 
Streptavidin HRP Rockland, PA USA 
2.1.7 Enzymes 
 
Restriction enzymes  MBI Fermentas, St. Leon-Rot, Germany 
Taq polymerase MBI Fermentas, St. Leon-Rot, Germany 
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2.1.8 Instruments 
Name  Company 
Agitator for bacterial cultures Edmund Buehler GmbH, Hechingen, 
Germany 
Camera system Spot CCD Diagnostic Instruments, Sterling Heights, 
USA 
Cell chamber neubauer improved Brand, Wertheim, Germany 
Centrifuge Sorvall RC5B Plus Kendro, USA 
Centrifuge Biofuge fresco Heraeus, Hanau, Germany 
DNA-agarose gel electrophoresis chamber Bio-Rad, Munich, Germany 
Eagle eye (Mididoc) Herolab, Wiesloch, Germany 
ELISA plate reader Anthos labtec, Wals, Austria 
FACS  Calibur Becton-Dickinson, Heidelberg, Germany 
Hyper processor (for processing films) Amersham, Freiburg, Germany 
Incubator for bacteria Melag, Berlin, Germany 
Incubator for cell culture Labotec, Goettingen, Germany 
Invert microscope DM-IL Leica, Bensheim, Germany 
LSM710 (laser scanning microscope) Zeiss, Goettingen, Germany 
Master cycler (PCR cycler) Eppendorf, Hamburg, Germany 
Magnetic stirrer 3000 Heidolph, Keilheim, Germany 
Microscope DMBRE Leica, Bensheim, Germany 
Microwave Phillips, Wiesbaden, Germany 
Photocassette Amersham, Freiburg, Germany 
Ph-Meter-761 Calimatic Knick, Berlin, Germany 
Photometer Ultraspec III Amersham, Freiburg, Germany 
Pipettus-Akku Hirschmann, Eberstadt, Germany 
Pipettes Eppendorf, Hamburg, Germany 
Powersupply PS 9009 GIBCO, Darmstadt, Germany 
Rotor GSA Kendro, USA 
Rotor SW34 Kendro, USA 
Rotor SW41 Ti Beckman Coulter, Krefeld, Germany 
Sterile bench Heraeus, Hanau, Germany 
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Sonicator Sonoplus Bandelin, Berlin, Germany 
Tabletop centrifuge Heraeus, Hanau, Germany 
Transferapparatus Mini Trans-Blot® Bio-Rad, Munich, Germany 
Thermo-mixer Eppendorf, Hamburg, Germany 
Homogenizer Bandelin Electronik, Germany 
UV-transilluminator Biotec Fischer, Germany 
Water-bath Julabo, Seelbach, Germany 
Weighing scale RC210 D Sartorius, Goettingen 
Whirlmixer Vortex Genie Si Inc., New York, USA 
 
2.1.9 Miscellaneous Materials 
Cell culture flasks 25cm2, 75cm2 Greiner, Frickenhausen, Germany 
Cell culture 96-well, 24-well, 6-well 
plates 
Greiner, Frickenhausen, Germany 
Centrifugal concentrators Vivaspin 6ml, 
20ml 
Vivascience, Hannover, Germany 
Cryovials Greiner, Frickenhausen, Germany 
Coverglass R. Langenbrinck, Emmendingen, 
Germany 
Falcon tubes 15ml, 50ml Greiner, Frickenhausen, Germany 
Needles BD Biosciences, Heidelberg, Germany 
Nitrocellulose membrane Hybond ECL Amersham, Freiburg, Germany 
Parafilm American Nat. Can., Greenwich, Great 
Britain  
Petriplates Greiner, Frickenhausen, Germany 
Pipette tips Sarstedt, Numbrecht, Germany 
Sterile filter 0,2µm Renner, Darmstadt, Germany 
Syringes BD Biosciences, Heidelberg, Germany 
Trans-well migration (Boyden) chambers 
48 well 
Neuroprobe, Gaithusberg, USA 
WhatmanTM 3MM paper Scleicher & Schull, Dassel 
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2.1.10 Chemicals: 
Acetic acid Riedel-de Haen, Seelze 
Acetone Fluka, Buchs, Switzerland 
Agarose Sigma, Steinheim 
Ammonium persulphate (APS) GIBCO, Darmstadt 
Ampicillin sulphate Calbiochem, Darmstadt 
Annexin FITC V Becton Dickinson,Heidelberg 
Bactoagar Fluka, Buchs, Switzerland 
Bio-Rad, Munich Bradford reagent Bio-Rad, Munich 
Biotin-X-NHS Calbiochem, Darmstadt 
Bovine Serum Albumin (BSA) PAA, Pasching, Austia 
Brij 96 Fluka, Buchs, Switzerland 
Bromo phenol blue Merck, Darmstadt 
Calcium chloride Merck, Darmstadt 
CFSE Invitrogen, Darmstadt 
Chloroform Riedel-de Haen, Seelze 
Coomassie R-250 Merck, Darmstadt 
Crystal violet Sigma, Steinheim 
Dimethyl formamide Merck, Darmstadt 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt 
Ethanol Riedel-de Haen, Seelze 
Ethidium bromide Merck, Darmstadt 
Ethylenediamine tetraacitic acid (EDTA) Sigma, Steinheim 
Fibronectin Sigma, Steinheim 
Foetal Calf Serum (FCS) PAA, Pasching, Austria 
Formaldehyde (37%) Merck, Darmstadt 
G418 sulphate  PAA, Pasching, Austria 
Gelatine (cold water fish skin) Merck, Darmstadt 
Glucose Merck, Darmstadt 
Ladder Gene ruler DNA MBI Fermentas, St. Leon-Rot 
Ladder Prestained Protein  MBI Fermentas, St. Leon-Rot 
L-Glutamine AppliChem, Darmstadt 
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Glycerine Roth, Karlsruhe 
Glycine GERBU, Gaiberg 
HEPES GERBU, Gaiberg 
HiPerfect-Reagent for transfection Quiagen, Hilden 
Hyaluronan SIGMA, Steinheim, Germany 
Hydrochloric acid (HCl) Riedel-de Haen, Seelze 
Hygromycin PAA, Pasching, Austria 
Hyperfilm ECL Amersham, Freiburg, Germany 
Isopropanol Fluka, Buchs, Switzerland 
Magnesium carbonate Merck, Darmstadt 
Magnesium chloride Merck, Darmstadt 
Magnesium sulphate Merck, Darmstadt 
Magnetic Beads Miltenyl Biotec,  Bergisch Gladbach, 
Germany 
Milk powder Roth, Karlsruhe 




Paraformaldehyde Sigma, Steinheim 
Penicillin Sigma, Steinheim 
Phenylmethylsulphonylfluoride (PMSF) Sigma, Steinheim 
Phorbolmyristateacetate (PMA) Sigma, Steinheim 
Propidium Iodide Sigma, Steinheim 
Potassium acetate Sigma, Steinheim 
Potassium carbonate Roth, Karlsruhe 
Potassium chloride Merck, Darmstadt 
Potassium dihydrogenphosphate Merck, Darmstadt 
Potassium tetrathionate Merck, Darmstadt 
Protease Inhibitor Cocktail Tablets Roche Diagnostics, Mannheim 
Protein G Sepharose 4 Fast Flow Amersham Biosciences, Freiburg  
Rotipherose Gel 30 (Acrylamide-mix) Roth, Karlsruhe 
RPMI 1640 GIBCO, Darmstadt cell culture 
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Silver nitrate Roth, Karlsruhe 
Sodium acetate Merck, Darmstadt 
Sodium azide AppliChem, Darmstadt 
Sodium carbonate AppliChem, Darmstadt 
Sodium chloride Fluka, Buchs, Switzerland 
Sodium hydrogen phosphate Merck, Darmstadt 
Sodium dodecyl sulphate (SDS) GERBU, Gaiberg 
Sodium hydrogen carbonate AppliChem, Darmstadt 
Sodium hydroxide Riedel-de Haen, Seelze 
Sodium pyruvate Merck, Darmstadt 
Sodium thiosulphate Merck, Darmstadt 
SP-Dio18(3) dye for exosome labelling Invitrogen, Darmstadt 
Tris Roth, Karlsruhe 
Triton-X-100 Sigma, Steinheim 
Trypan bue Serva, Heidelberg 
Trypsin Sigma, Steinheim 
Trypton AppliChem, Darmstadt 
Tween 20 Serva, Heidelberg 
Yeast Extract GIBCO, Darmstadt  




10mM HEPES pH7.4, 140nM NaCl, 25mM CaCl2 
Bicarbonate buffer pH 
9.6 
15mM Na2CO3, 35mM NaHCO3. Fill to 900ml with distilled 
water. Adjust pH to 9.6 and make it upto 1l with water. 
Blot buffer (5x) 10g SDS, 142g Glycine, 30.3g Tris base and make upto 1l with 
distilled water. 1X buffer was made fresh by taking 5x Blot 
buffer, methanol and distilled water in the ratio 1:1:3 
Cell culture complete 
medium 
RPMI 1640 medium, 10% FCS, 1% Glutamine, 1% Penicillin/ 
Streptomycin antibiotic solution, additional antibiotic if needed. 
DEPC water 200µl DEPC reagent in 1l distilled water and autoclave 
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Ethidium Bromide 0.2g Ethidium bromide, distilled water 20ml. Stored in dark. 
Freezing medium 90%FCS, 10%DMSO 
Glycine solution 0.2M glycine in PBS 
HEPES buffer 25mM HEPES pH7.2, 150mM NaCl, 5mM MgCl2, 1mM 
PMSF, 1x Protease inhibitor, 1mM NaVO4, detergent as 
indicated in experiments 
LB medium 10g Peptone, 5g Yeast extract, 10g NaCl, fill upto 1l with 
Distilled water. For LB plates 15g agar was added. 
Laemmli buffer  62.5mM Tris HCl pH 6.8, 25% glycerol, 2% SDS, 0.01% 
bromophenol blue 
PBS (pH7.2) 137mM NaCl, 2.7KCl, 4.3mM Na2HPO4 in distilled water 
Running buffer for 
protein gels (10x) 
 10g SDS, 144g Glycine, 30g Tris, filled upto 1l with distilled 
water 
TAE Buffer 242g Tris base, 57.1ml Glacial acetic acid, 100ml 0.5m EDTA 
pH 8.0, Add distilled water 1l and adjust final pH to 8.5.  
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2.2 Methods 
2.2.1 Molecular biology 
2.2.1.1 Chemically competent cells  
From a 50 ml DH5α overnight culture, 1 litre of LB medium (without antibiotic) was 
cultivated till the OD 600nm  reaches 0.5-0.6.  Cells were then centrifuged in the 
Sorvall GSA rotor (250 ml centrifuge bottle) at 5,000 RPM for 10 minutes at 4oC, 
bacteria pellet was gently resuspended in 1/4 volume of ice cold sterile MgCl2.  Cells 
were again centrifuged at 4000 RPM in the Sorvall GSA rotor for 10 minutes and 
bacterial pellet was now re-suspended in 1/20 volume of ice cold CaCl2.  Cells were 
centrifuged at 4,000 RPM in the GSA rotor for 10 minutes and the cell pellet was re-
suspended in 1/50 volume of ice cold, sterile  85 mM CaCl2 in 15% glycerol 
w/v. Cells were aliquoted  in 50 µl each and stored  at -80oC. 
 
2.2.1.2 Transformation 
Competent cells were thawed on ice and 1-10ng of plasmid was added and incubated 
on ice for 30 mins. Competent cell plus plasmid was given a heat shock at 42°C for 2 
mins and kept on ice for another 5 mins. To this 1 ml of LB medium (no antibiotics) 
was added and kept at shaker for 1 hr at 37°C. 10 to 100 µl was then plated on LB 
agar plate containing selection drug (ampicilline at 100µg/ml). Plates were incubated 
overnight at 37°C. 
 
2.2.1.3 Mini-Prep 
Single colonies were recovered from LB agar plates in 2 ml LB medium containing 
selection agent (ampicilline at 100µg/ml) on a shaker set at 200 rpm at 37°C 
overnight.1 ml bacterial suspension was used for miniprep following producer’s 
recommendations (Miniprep kit, Qiagen). Positive clones were obtained by doing 
enzymatic digestion. 
 
2.2.1.4 Enzymatic restriction digestion 
For double digestion 1 µg purified plasmid with insert was mixed with 0.5µl (5U) 
primary restriction enzyme and appropriate digestion buffer (1X). Total volume was 
made up with distilled water to 10 µl and digestion was performed for 2 hrs in a water 
bath at 37°C. After digestion, DNA was purified over Qiagen mini-column and a 
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second enzymatic digestion was performed following the same procedure. Samples 




To obtain sufficient amount of vector DNA necessary for transfection, overnight 
cultures of positive clones were incubated overnight on a shaker set at 200 rpm at 
37°C in 100ml of LB medium containing appropriate selection antibiotic (ampicillin 
at 100µg/ml). Whole bacterial culture was used for midi-prepration following 
producer’s recommadations (Midi-prep Kit, Qiagen). 
 
2.2.1.6 Isolation of DNA fragment from agarose gel  
The DNA fragments were separated on agarose gel and were illuminated with UV-
light. The desired band was excised using a clean scalpel and transferred into 1.5ml 
tube. The DNA was purified from the excised agarose gel using Qiagen gel extraction 
kit following manufacturer’s protocol. 
  
2.2.1.7 Quantification of DNA  
DNA was quantified spectroscopically using a Spectronic-Unicam spectrophotometer. 
Concentration was determined by measuring the absorbance at 260nm and 280nm. 
Absorbance at 260nm should be higher than 0.1 but less than 0.6 for reliable 
determinations. A ratio of A260/A280 between 1.8 and 2 indicated a sufficient purity 
of the DNA preparation. 
 
 2.2.1.8 RNA preparation, cDNA synthesis and amplification 
Total RNA isolation was done from 107 cells with Tri reagent following 
manufacturer’s instructions (Applichem, Darmstadt, Germany). Quality of RNA 
preparation was checked by running RNA sample diluted in RNA sample buffer on 
1% agarose/formaldehyde gel. cDNA synthesis and amplification was performed by 
RT–PCR (reverse transcriptase polymerase reaction). 1-2 µg template RNA was 
mixed with 0.5µg oligo dT primer and heated at 70°C, 5 min; chilled on ice, then 
mixed with 1µl Im Prom II reverse transcriptase (10U), 1-2mM dNTP, 1x Im Prom II 
buffer 5x, 6mM MgCl2 and made upto a total of 20µl with nuclease free water. The 
program continues as 25°C-5min, 42°C-60min and 70°C-15min.  
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PCR was performed in 25 µl volume containing template, 1-2 mM dNTP, 1.5µl Red 
Taq polymerase, 2.5 µl 10x Taq buffer and 0.2 µM primer forward and reverse. Total 
volume was completed to 25 µl with autoclaved distilled water. 
PCR Program: 
wtCD44 :  94°C-5min, 94°C-30secs, 55°C-30secs, 72°C-1min -32cycles, 72°C-10min 
mutCD44 : 94°C-5min, 94°C-30secs, 50°C-30secs, 72°C-1min, 22cycles, 72°C-   
10min 
truncCD44 :94°C-5min, 94°C-30secs, 53°C-30secs, 72°C-1min -22 cycles, 72°C- 
10min 
wtCD49d : 94°C-5min, 94°C-30secs, 55°C-30secs, 72°C-3.5min -32 cycles, 72°C-
10min 
mutCD49d : 94°C-5min, 94°C-30secs, 54°C-30secs, 72°C-3.5min, 22cycles, 72°C-
10min 
GAPDH :  94°C-5min, 94°C-30secs, 55°C-30secs, 72°C-1min -32 cycles, 72°C-
10min 
 
2.2.1.9 Site directed Mutagenesis  
Site-directed mutagenesis is performed by using mutagenic primers (b and c) and 
flanking primers (a and d) to generate intermediate PCR products AB and CD that are 
overlapping fragments of the entire product AD. Products AB and CD are denatured 
when used as template DNA for the second PCR; strands of each product hybridize at 
their overlapping, complementary regions that also contain the desired mutation 
(indicated by the cross). Amplification of product AD in PCR #2 is driven by primers 
a and d. Final product AD is inserted into pcDNA3 vector (gray circle) to generate 
larger quantities of DNA. 
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Restriction sites were introduced into the mutated primers (CD49dmut MluI) to 
confirm the efficacy of mutants. Care should be taken that these sites should be 
unique (should not be present in insert and vector) and should not make any change in 
the protein structure, 
2.2.1.10 DNA gel electrophoresis 
PCR products or samples containing DNA of interest were checked by running an 
agarose gel of 1 to 2%, depending on the size of the product. When Red Taq 
polymerase was not used then DNA sample was mixed with DNA loading dye (6x) to 
locate the running front. Markers (1kb or 100bp) were run in parallel. The gel was run 
at 100 volts in a migration tank containing 1x TAE buffer. Bands were visualized on a 
U.V. transilluminator. 
2.2.2 Protein Chemistry 
2.2.2.1 Antibody purification  
Antibody purification was done by affinity chromatography using a sepharose protein 
G-4B column. To purify IgG fractions, sterile filtered hybridomas supernatants were  
passed over a sepharose protein G-4B column. The column was washed with 0.1M 
phosphate buffer, pH 7.5. Bound IgG was eluted from the column with 0.1M Glycine 
buffer pH 2.7. Protein containing fractions were dialyzed against PBS, concentrated 
and filter-sterilized. The protein amounts obtained were photometrically analysed for 
protein concentration by Biorad assay. 
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2.2.2.2 Biorad assay  
This test is based on the affinity of the  coomassie dye G-250 for proteins. In 
microassay it allows detections of BSA amounts under 25µg/ml. To proceed with 
detection of the soluble proteins, 1µl of each sample to test were diluted in a flat 
micotiter well with 99µl Biorad reagent prediluted (1 :10 in distilled water). In 
parallel, a 10mg/ml BSA solution in water was serially diluted to allow drawing of a 
standard curve. After 5min incubations, optical densities were read at 595nm on an 
ELISA reader. Optical densities were reported to the standard curve for concentration 
calculation. 
2.2.2.3 SDS- polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein components were separated using SDS polyacrylamide gel electrophoresis 
(SDS-PAGE). SDS, an anionic detergent denatures and imparts negative charge to all 
proteins in the sample. Proteins can be separated according to their size in an 
electrical field.  Two gels were used for this purpose. At the bottom resolving gel was 
poured to separate the proteins and at the top a stacking gel. The stacking gel 
concentrates all proteins in one band and allows them to enter the resolving gel at the 
same time; it can be mounted with a comb to load samples in the wells.  Before 
loading the gel, samples were boiled for 5 minutes at 95° C for proteins to allow 
complete protein denaturation. Around 25-30 µl of sample was loaded into wells. The 
inner and outer chambers were filled with running buffer (1x). 
2.2.2.4 Immunoprecipitaion 
Freshly harvested cells from lymph node, spleen or cultured cells (107) were taken,  
washed 3 times in cold PBS. Cells were lysed in 1ml HEPES buffer containing 
protease inhibitor and phosphate inhibitors as well as detergent  (1% Lubrol) for 1 
hour at  4°C on a rocking plate-form.  Lysates were then centrifuged 10min at 13,000 
rpm, 4°C. Lysate supernatants were collected. Immunoprecipitation was done using 1 
to 5 µg specific monoclonal or polyclonal antibodies at 4°C on a rocking plate-form 
for over night. Following over night incubation at 4°C, 5% of protein G-sepharose 
was added to the precleared lysates for 1 hour. Protein G coupled antibody was 
washed 3 times with lysis buffer completed with detergent. Sepharose pellet was 
resuspended in 80µl Laemmli buffer and boiled 5min at 95°C. After 1min 
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centrifugation at maximum speed, 20µl of the supernatant were taken and loaded on 
acrylamide gel to be resolved by SDS-PAGE. If indicated, cells were biotinylated 
before lysis and immunoprecipitation. Washed cells were resuspended in HEPES 
buffer containing 0.1mg/ml NHS-water soluble biotin. Biotinylation was performed 
30min under agitation at 4°C. The reaction was terminated by 3 washes with 0.2M 
glycine PBS solution. Cells were lysed 1 hour at 4°C in 1ml HEPES buffer containing 
protease and phosphatases inhibitors as well as detergent of choice. Following steps 
were similar as described above. 
2.2.2.5 Western Blotting 
Following gel electrophoresis proteins were electroblotted onto a nitrocellulose 
membrane (Amersham Biosciences) overnight at 30 volts and analysed by 
immunoblotting using specific primary and secondary antibodies. The gel, foam pads 
and 3MM Whattmann papers were equilibrated in blotting buffer; the gel was placed 
on the membrane which in turn was placed on Whattmann paper followed by foam 
pads on either side. The whole set was placed in a cassette holder, followed by a tank 
blotting apparatus such that the membrane was placed towards the anode side. After 
overnight transfer the blots were blocked with PBS/5% milk powder or BSA (for 
phosphospecific antibodies) for 1 hour, followed by primary antibody for 1 hour. 
Blots were washed with PBS/0.1%Tween thrice and 5 minutes each wash. Then the 
blots were incubated in secondary antibody for an hour, followed by washing again. 
The blots were developed with Enhanced Chemiluminescence system (ECL, 
Amersham Biosciences) and exposed to X-ray film (Amersham Biosciences) for 
desired time points and developed.  
2.2.3 Cell biology 
2.2.3.1 Cell culture 
Cells were grown in a humidified incubator at 37°C, 5% CO2. Cells were maintained 
in RPMI 1640 medium in 10% FCS as per the requirements. Cells were usually 
passaged at a ratio of 1:4.  For long term cell storage, cells were washed once with 
medium and frozen in cryovials in FCS, 10% DMSO. The vials were placed for 1 
hour at -80°C before transferring into liquid nitrogen. Cells were thawed from the 
cryovials by placing the vials from liquid nitrogen first on ice, followed by 37°C 
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water bath and immediately placed in falcon containing medium and centrifuged at 
1600 rpm for 5 minutes. The medium was sucked off and new medium was added and 
transferred to flasks at high density to maximise recovery. 
Cell viability was determined using hemacytometer and trypan blue staining. 
Tryptan blue: 0.4% Trypan blue (4vol) 
                       4.5% NaCl (1vol). 
2.2.3.2 Transfection of suspension cells 
107 Jurkat cells or/and El4 cells were washed in cold serum-free RPMI. Cells were 
then resuspended in 200 µl serum-free RPMI, kept on ice (Jurkat cells) or at room 
temperature (EL4 cells) in 0.4 cm electroporation cuvette for 10 mins. 10-15 ug of 
sterile DNA is added to the cells in the cuvette and mixed. Electroporation was done 
at 250 V, 960 µF. After the pulse cuvette is kept on ice (Jurkat cells) or at room 
temperature (EL4 cells) for 10 min. Later cells were plated in 1 ml of RPMI+10%FCS 
without antibiotic mix for 12 hrs and then were plated in 1ml of complete medium 
with 750µg/ml (Jurkat cells) and 250µg/ml (El4 cells) G418. Cells were tested within 
48 hrs for the transfection efficiency via flow cytometry. Once positive for the desired 
protein, cells were kept in culture for another 2 weeks and can be subjected to single 
cell cloning. 
 
2.3.3 Single cell cloning 
Single cell cloning can be done by single cell per well seeding or by serial dilution 
using 96 well plate in RPMI+10%FCS+G418 medium. For serial dilution 5x104 cells 
were plated in a single well of 96 well plates and were serially diluted down the lane. 
After 4 weeks clones were checked by flow cytometry, positive clones were 
expanded.  
 
2.2.3.4 Magnetic Beads separation 
Spleen cells and lymph node cells were prepared as described below. CD11b+/Gr1+ 
spleen cells were enriched by magnetic bead isolation. T cells were enriched in LNC 
by magnetic bead depletion of CD11b+, CD19+, and CD16/CD32+ cells. 
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2.2.3.5 Flow cytometry 
Fluorescent activated cell sorting (FACS) allows cell segregation based on size and 
granulation and also allows detecting the expression levels of proteins in cells. This 
method is based on diffraction of light and measure of fluorescence, which reflects 
cell size and amount of fluorescent antibody labelled cells. 
Cells were washed in PBS/0.5% BSA. About 5x105 cells were added to round 
bottomed 96 well plates. After centrifugation cells were suspended in 50 µl of primary 
antibody diluted in PBS/0.5% BSA and incubated for half an hour on ice. This was 
followed by washing the cells thrice with PBS/0.5%BSA, 5min each wash. Secondary 
antibody (50µl) coupled to fluorochrome was added to each well and incubated for 
half an hour on ice in the dark. The cells were again washed. After the last wash cells 
were suspended in 200µl PBS/0.5%BSA for immediate measuring. Staining was 
evaluated using FACS-Calibur (Becton Dickinson, Heidelberg, Germany).  In case of 
double or triple fluorescence the same procedure was repeated with adequate 
antibodies and blocking steps wherever necessary (e.g. different antibodies from the 
same species). 
For cytokines, intracellular FACS was performed. The cells were first incubated with 
formalin 1% to fix them for 10 minutes on ice. The cells were washed with PBS 1% 
BSA 3X as mentioned above. Thereafter the cells were incubated with 0.1 % Tween 
for 15 minutes on ice to create pores on the cell membrane and facilitate the entry of 
antibodies against the cytokines into the cells. The cells were again washed and 
antibodies were added following the usual protocol. 
 
2.2.3.6 Immunohistochemistry 
Immunoassay was performed on 5µm cross-section for skin tisues. The section was 
fixed with choloroform/acetone (1:1) for 4 mins. The endogenous peroxidase 
reactivity was blocked by washing with levamisole solution. Sections were fixed with 
4% PFA, after washing with PBS, non-specific binding was blocked with 2% normal 
serum derived from the same species as the secondary antibodies. The sections were 
washed with PBS followed by incubating in secondary biotinylated antibody for 30 
min. After 3 washing of 15 mins each section was incubated with avidin-biotin 
complex. After washing with PBS, the sections were detected by staining with AEC 
reagent. The reaction was terminated by adding water. Sections were counterstained 
with Mayer’s hematoxylin and mounted afterwards. 
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2.2.3.7 Migration assay 
Cell lines and LNC were freshly prepared. The cells were counted and 5x104 cells 
were incubated with or without anti-CD44, anti-CD49d and PMA for 30 mins on ice 
and then were seeded onto the upper well of a boyden chamber in 30 µl of RPMI 
without FCS. The lower part of the chamber is separated by a 5µm (LNC) and 8µm 
(cell lines) pore sized polycarbonate membrane. The lower part of chamber contained 
chemotaxis buffer with or without HA (5µg/ml), FN (250µg/ml). The chamber was 
incubated in 5% CO2 at 37oC for 4 hrs and cells in the lower chamber were counted 
by hemacytometer and trypan blue staining. 
 
2.2.3.8 Coating of plates for crosslinking 
HA (10µg/ml) and FN (50µg/ml) in bicarbonate buffer was used to coat 6-well plate 
(1ml) or 96-well plate (100µl). Plates were kept at 4οC o/n or at 37οC for 1 hr, plates 
were than washed 2X with PBS+0.1%BSA and blockd with PBS+1%BSA for another 
1 hr at 37οC. Washed 2X with PBS+0.1%BSA and can be stored in the same washing 
buffer untill use, at 4οC. 
 
2.2.3.9 Apoptosis assay 
Apoptosis assay was performed using Annexin V-FITC and propidium iodide (PI) (R 
& D systems, Wiesbaden-Nordenstadt, Germany) double staining. Early apoptotic 
cells bind to Annexin V because of the exposed phosphatidylserine on the outer cell 
membrane. Late apoptotic cells are positive for Annexin V and PI. Necrotic cells bind 
only PI. LNC (1x105, triplicates) were co-cultured with and without MDSC. Cultures 
contained AA skin lysates (100µg/ml) or PMA (10-8M)/ionomycin (10-6M). Cell lines 
were activated over crosslinked HA, FN and with PMA and were treated with or 
without anti-CD44 and anti-CD49d. Apoptosis was determined after 48h by 
AnnexinV/PI staining, 96-well plates were centrifuged at 1600 rpm for 5 minutes and 
washed with PBS/1% BSA. Cell labelling was performed according to manufacturer’s 
instructions. Cell were incubated in the dark at RT for 15 min and detected by FACS 
using the FL1 channel for Annexin FITC and FL-3 channel for PI. 
 
2.2.3.10 Proliferation assay 
LNC (1x105, triplicates) were co-cultured with and without MDSC. Cultures con-
tained AA skin lysates (100µg/ml) or PMA (10-8M)/ionomycin (10-6M). Cell lines 
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were activated over crosslinked HA (5µg/ml) and FN (250µg /ml) and with PMA (10-
8M)/Ionomycin (10-6M) in solution  and were treated with or without anti-CD44 and 
anti-CD49d to check for the proliferative activity, cells were evaluated for 72 hour in 
the presence or absence of anti-CD44 or anti-CD49d by 3H-thymidine incorporation. 
 
2.2.3.11 Cytosol, nuclei and mitochondria preparation 
Cells were incubated in hypotonic buffer, homogenized and centrifuged at 800rpm for 
pelleting the nuclei. For separating the cytosolic from the mitochondrial fraction, 
2.5x106 cells were lysed in 0.5ml lysis buffer. After adding Nonidet-P40 (0.5%), 
vortexing, and centrifugation (1600rpm, 5min), cytosolic proteins were recovered 
from the supernatant. The pellet (mitochondria) and the pelleted nuclei were washed, 
resuspended in lysis buffer (1% TritonX-100, 1% SDS) and sonicated (7sec, 9cycles). 
 
2.2.4 Animal experiments  
2.2.4.1 Skin Transplantation 
Donor mouse was sacrificed and recipient mice were anesthesized by injecting 0.12-
0.15ml ketamine i.p. Antero-posterior midline of the graft recipients was shaved. 
Disinfection of mice before grafting was done with the ethanol pad. For grafting 1 cm 
pieces in diameter of alopecia areata affected skin from the donor were cut and 
collected in PBS (till donor mice are ready). The recipient mice were cleaned with 
iodine solution at the area shaved before making any surgery. Round piece of skin 
from the graft recipient were removed from antero-posterior midline (shaved area). 
Graft was put onto the gap, stiches were made on four sides (with 3 knots each) and 
the gaps were sealed with histoacryl-glue. Bandages were applied once glue is dry. 
Mice drinking water was supplied with antibiotic Sulfadimidin (1g in 1L water) from 
day 0 (grafting day) to day 4 and from day 7 to day 11 after grafting. 
To look for effect of MDSC on hair re-growth, mice received MDSC (1x107, i.v.) or 
an ATRA depot pellet (sub cutaneous). Both applications were repeated after 3 weeks. 
 
2.2.4.2 Lymphatic organ preparation 
Lymph nodes and/or spleen were collected in the medium (RPMI) or PBS +1%FCS 
from 16-20 weeks old mice. Organs were meshed on the sterile gauze and washed the 
gauze 2-3 times with sterile medium. Cells were collected in 50 ml of RPMI medium 
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supplemented with 1% FCS and cells were centrifuged at 1600rpm for 5 minutes. 
Now these cells can be used for further experiment. 
 
2.2.4.3 Skin infiltrating leukocytes (Skil) preparation 
Skin is taken from whole of the back and is made free from fat, tissue and hair. Skin is 
first treated with trypsin (1mg/ml) for 30 min at 37°C and then pressed (epidermis) 
onto the sterile gauge (very harshly), cells were collected and washed with medium 
(RPMI) two times. This procedure was repeated 3 times and then cells were pooled 
and kept at 37°C for 2 hrs or o/n in RPMI 1640 medium supplemented with 10% 
FCS, antibiotic mix to rejuvenate them.   
 
2.2.4.4 Skin lysate preparation 
Skin is taken from whole of the back and is made free from fat, tissue and hair. Skin 
was then cut into very small pieces with scalpel and was homogenized with help of an 
ultra turrax in 5 ml of ice cold PBS. Lysates were centrifuged at 2000rpm for 15 mins 
to settle down the debris and were frozen at -200C until use. 
 
2.2.4.5 Delayed type hypersensitivity (DTH) reaction 
Whole back of the mice was shaved and sensitized by applying 1% SADBE (squaric 
acid dibutylester) in acetone on the dorsal side (back) 3-4 times with the help of 
cotton bud. Mice were then weekly sensitized by topical applications of 0.5% SADBE 
in acetone on the back and the abdominal wall to induce a moderately severe contact 
dermatitis lasting for 2–3 days. Mice were challenged 3-4 times. The skin becomes 
red, swollen, itchy, or blistered. This kind of skin reaction is a sign that the contact 
sensitizer has worked. Mice were sacrificed by cervical dislocation 3 days after the 
last challenge. 
 
2.2.5 Statistical analysis 
Significance of differences was calculated according to the Student's T test (in vitro 
studies). Functional assays were repeated at least 3 times. Mean±SD of in vitro 
studies are based on 3-4 replicates. 
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3. Results 
Autoimmune diseases are frequently characterized by persisting activation and 
expansion of autoreactive T cells as well as resistance towards activation induced cell 
death. This also accounts for alopecia areata, an autoimmune disease affecting anagen 
stage hair follicles, where the topical application of contact sensitizers presents the 
most efficient therapy in human as well as in a mouse model (257-259). I tried to 
answer particularly two questions, first what are the molecular mechanisms that 
allows for persisting T cell activation and second, how can the induction of an 
immune disorder, chronic contact eczema, be a therapeutic for another immune 
disorder, an organ related autoimmune disease. 
 
3.1 Persisting T cell activation 
I started with the first question, the persisting activation and expansion of T cells. In 
the healthy organism antigen-specific T cells become activated via TCR/CD3 
complex and co-stimulatory signals. Activated T cells become regulated by transient 
TCR internalization, inhibitory T cells such as regulatory T cells (Treg) and a 
mechanism called activation induced cell death. Alternatively to T cell activation via 
the TCR/CD3 complex, though not mutually exclusive, there is some evidence that T 
cells could become activated circumventing TCR engagement. Such an alternative 
mechanism could explain the escape from regulatory mechanisms and provides a 
means for persisting T cell activation and expansion as frequently seen in autoimmune 
diseases. I explored this question with T cell lines, which has the advantage of a 
uniform population of T cells and offers the opportunity to modulate individual 
molecules. In addition, I selected a T cell leukaemia, which expresses the TCR/CD3 
complex and a thymoma, which does not express the TCR/CD3 complex. This 
allowed me to distinguish between TCR-dependant versus TCR-independent effects.  
CD44 and CD49d can act as accessory molecules supporting TCR-initiated activation 
signals.Yet, they have also been suggested to contribute to TCR-independent T cell 
activation. In fact, previous work in our lab provided evidence that these two 
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3.1.1 Selection of an appropriate model system 
To explore the activity of CD44 as well as the suggested joint activities of CD44 and 
CD49d, I selected EL4 (Thymoma cell line) cells which are CD44+ , CD49d- and 
TCR/CD3- and Jurkat cells (Leukemia T cell line) which are CD44-, CD49d+ and 
TCR/CD3+ and for comparison naïve and activated LNC (Fig.1). Jurkat cells were 
transfected with CD44, CD44 mutated at position Ser325 and Ser291 (mutCD44) or 
CD44 without cytoplasmic tail (truncCD44). The mutCD44 will prohibit ezrin 
binding, since binding of ezrin requires an exchange of Ser325 versus Ser291 
phosphorylation (202), truncCD44 will prohibit binding of all cytosolic linker and 
signal transduction molecules. This will also provide evidence, whether the HA 
binding form of CD44 (activated form) is essential for the association with CD49d. 
EL4 cells were transfected with CD49d or CD49d mutated at position Ser988 
(mutCD49d). The latter will interfere with CD49d phosphorylation and prevents 
paxillin and FAK binding (260,261).       
              
                     
Figure1. CD44, CD49d and CD3 expression in EL4 and Jurkat cells: EL4, Jurkat and for 
comparison LNC from naïve (control) and AA mice were stained with the indicated antibodies and 
expression was checked by flow cytometry. 
 
3.1.2 Cloning of CD44 and CD49d mutants 
Cloning of CD44 without cytoplasmic domain (truncCD44): 
As the first step wild type murine CD44 was re-cloned in pcDNA3 vector. Restriction 
digestion with EcoRI and XhoI confirmed correct insertion of wild type CD44 (1.2  
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Kb) (Fig.2A). This plasmid was used for constructing the CD44 mutants- without 
cytoplasmic tail (truncCD44) and CD44 mutated at Ser291 and Ser325 to alanine 
(mutCD44). 
 For the construction of CD44 tailless mutant, a gradient PCR was performed for an 
appropriate annealing temperature. A good amplification was obtained at all the tested 
temperatures (Fig.2B). The amplified products were ligated to pcDNA3 at restriction 
sites EcoRI and XhoI and ligation was confirmed by restriction digestion with the 
same set of enzymes (Fig.2C), positive clones were confirmed by sequencing.  
 
           
 
Figure2. Amplification of CD44 excluding the cytoplasmic domain (truncCD44): (A) Confirmation 
of wild type CD44 in pcDNA3 by restriction digestion with EcoRI and XhoI at 37ο C for 2 hrs. The 
products were run on 1% agrose gel. The desired fragment was obtained at 1.2 kb. (B) Gradient PCR 
for truncated CD44. CD44 plasmid from (A) was used as a template for gradient PCR at 50οC, 53οC 
and 55οC. Amplified products were run on 1% agrose gel. The desired product was obtained at 1kb. (C) 
Amplified products were cloned in pcDNA3 and clones were confirmed by restriction digestion with 
EcoRI and XhoI at 37ο C for 2 hrs. The products were run on 1% agrose gel. The desired fragment was 
obtained at 1 kb. 
 
 
Cloning of mutated CD44 at Ser291 and Ser325 to alanine 
 
The CD44 wild type plasmid described above was used as a template for 
amplification with the primers with the desired base pair changed from AGT (Serine) 
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to GCT (Alanine). It was done in two parts; first mutation at Ser325 was introduced 
followed by the mutation at Ser291. Amplification using forward primer (F) and 
reverse primer with the mutation (Rm); reverse primer (R) and forward primer with 
the mutation (Fm) was performed, desired DNA amplification was obtained at 1.0 kb 
and 210 bp, respectively (Fig.3A). These amplified products were ligated with each 
other and were used as template for the second amplification using forward and 
reverse primer. The desired DNA fragments were obtained at 1.2 Kb (Fig.3B). The 
amplified products were ligated to pcDNA3 at restriction sites EcoRI and XhoI. 
Ligation was confirmed by restriction digestion with EcoRI and XhoI (Fig.3C). 
Positive clones were confirmed by sequencing. A positive clone from the first 
mutation was used as template for the second mutation at Ser291 and was cloned in 
pcDNA3. Restriction digestion with EcoRI and XhoI was performed to confirm the 
positive clone (Fig.3D). Positive clones were confirmed by sequencing (Fig.3E).    
 










Figure3. Cloning of CD44 mutated at Ser291 and Ser325 positions: (A) Amplification for the first 
mutation (Ser325) was done at annealing temperature 50ο C using wt CD44 as template with forward 
primer F+ reverse primer with mutated base pair Rm (1kb) and reverse primer R+ forward primer with 
mutated base pair Fm (210). Products were run on 1% agrose gel. (B) Second amplification was done 
using template from (A) with forward and reverse primer. (C) The amplified product was cloned into 
pcDNA3. Restriction digestion was done with EcoR1 and Xho1 at 37ο C for 2 hrs. The desired 
fragment was obtained at 1.2 kb. (D) The second mutation (Ser291) was done using a positive clone 
from (C), amplification was done using primers as in (A), amplified products were cloned in pcDNA3 
and restriction digestion was done with EcoR1 and Xho1 at 37ο C for 2 hrs, products were run on 1% 
agrose gel. The desired fragment was obtained at 1.2 kb. (E) Sequence analysis of the positive clone, 
desired mutations are shown with boxes. 
 
Cloning of mutated CD49d at Ser988 to alanine 
 
For inducing mutation in CD49d (3.5 kb) at Ser988 to alanine, wild type CD49d was 
used as template and amplification with the primers with the desired base pair 
changed from TCT (serine) to GCT (alanine) was performed. First, by using forward 
primer (F) and reverse primer with the mutation (Rm), second, using reverse primer 
(R) and forward primer with the mutation (Fm). The desired DNA amplification was 
obtained at 3.4 kb and 75 bp, respectively (Fig.4A). These amplified products were 
ligated to each other and used as template for the second amplification reaction.The 
desired DNA fragments were obtained at 3.5 Kb (Fig.4B). Amplified products were 
ligated to pcDNA3 at restriction sites EcoRI and XhoI. Ligation was confirmed by 
restriction digestion with EcoRI and XhoI (Fig.4C) and with MluI and EcoR1 
(Fig.4D), which was introduced into the mutated primer. Positive clones were 
confirmed by sequencing (Fig.4E). 
                                                                                                                              Results 
 71




Figure4. Cloning of CD49d mutated at Ser988: (A) Amplification was done with forward primer F+ 
reverse primer with mutated base pair Rm (3.4 kb) and reverse primer R+ forward primer with mutated 
base pair Fm (75 bp). Products were run on 1% agrose gel. (B) The second amplification was done 
using template from (A) with forward and reverse primer.  (C, D) The amplified product from (B) was 
cloned into pcDNA3 and restriction digestion with (C) EcoR1 and Xho1and (D) MluI at 37οC for 2 hrs 
was done. Samples were run on 1% agrose gel. The desired fragment was obtained at 3.5 kb. (E) 
Sequence analysis of positive clone, the desired mutation is shown with box. 
 
3.1.3 Efficacy of transfectants  
EL4 and Jurkat cells were stably transfected with non-mutated and mutated CD49d 
and CD44, respectively. Both lines showed high and comparable expression of CD44 
and CD49d. Furthermore, transfection-induced expression was well in the range of 
native expression in activated leukocytes (Fig.5 A, B).  
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Figure5. Efficacy of transfection: (A) Transfection efficiency was checked by flow cytometry. EL4, 
EL4-CD49d, EL4-mutCD49d, Jurkat, Jurkat-CD44, Jurkat-mutCD44, Jurkat-truncCD44 cells were 
stained with the indicated antibodies. (B) Cells were lysed and were run on SDS-PAGE, proteins were 
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3.1.4 Characterization of transfected lines 
 
As a prerequisite to define the impact of CD44-CD49d cooperativity on leukocyte / 
leukemia migration, activation and apoptosis resistance, it was mandatory to define 
the expression profile of adhesion molecules, T cell and T cell activation markers in 
EL4 and Jurkat cells and to control for possible alterations in expression by 
transfection of CD49d and CD44, respectively. EL4 cells along with CD44, express 
other adhesion molecule CD18 (β2), but do not express selectins and express CD54 
(ICAM1) at medium level. EL4 cells hardly express β1 integrins like CD49a (α1β1), 
CD49b (α2β1), CD49c (α3β1), CD49d (α4β1), except for low level expression of 
CD49f (α6β1). Expression of none of these molecules is altered by CD49d 
transfection. Jurkat cells do not express CD44. They express CD18 (β2)  at a low level 
as well as β1 integrins CD49a, CD49b, CD49c, CD49d and CD49f, strongest 
expression being seen for CD49c and CD49d. Jurkat cells weakly express selectin 
CD62P (P-selectin), but not CD62L (L-selectin) and CD62E (E-selectin). They 
express CD50 (ICAM3) and CD54 (ICAM1) at a high level. Expression is not altered 
by CD44 cDNA transfection (Fig.6A-C). 
EL4 cells do not express the T cell receptors TCRαβ or TCRγδ chains or CD3, but 
express CD4 (helper T cell specific for MHC classII) and CD8 (cytotoxic T cell 
specific for MHC class I) at high levels. This is in line with their origin from thymus, 
where early pre-T cells express CD4 and CD8 shortly before TCR and CD3 complex 
expression. Jurkat cells express CD3 and CD4. 
 Besides adhesion molecules, it was also important to know the expression of so 
called accessory molecules, which support the TCR complex. EL4 cells express CD25 
at a high level and CD28, CD69 at medium level, and CD154 and CD152 at a low 
level. Non-transfected Jurkat cells express CD69, CD154 at high level and CD152, 
CD25 and CD28 at medium level. Expression of these molecules is unaltered after 
CD44 cDNA transfection (Fig.6D, E).  
Both EL4 and Jurkat cells express the cytokines IL2 and IL12 which are involved in T 
cell activation. Only EL4 cells express IFNγ and TNFα at a high level. Expression of 
these cytokines is low in naïve lymphocytes, but increased in AA LNC (Fig.6F-H). 
Finally and in view of the question on apoptosis induced cell death, it should be noted 
that Jurkat cells express the apoptosis receptor CD95 (death receptor), and its ligand 
CD95L (death receptor ligand), CD120a (TNF receptor) which binds to TNF and 
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mediates apoptosis) and CD284 (Toll like Receptor-4). EL4 cells only express CD254 
(TNFR ligand expressed by helper T cells). Naïve lymphocytes express CD95 and 
CD254 at a medium high level. Expression of CD254 is decreased in AA LNC, 
CD95L and CD284 expression is increased in AA LNC (Fig.6I-K). 
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Figure6. Characterization of the transfected El4 and Jurkat cell lines: LNC from naïve (control) 
and AA mice and El4, El4-wtCD49d, EL4-mutCD49d, Jurkat, Jurkat-wtCD44, Jurkat-mutCD44, 
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Taken together, transfected EL4 and Jurkat cells express native and mutated CD49d, 
CD44, respectively at a comparably high level. With the exception of CD120a 
(TNFRI), which is downregulated in CD44 cDNA transfected Jurkat cells, adhesion 
molecule, T cell and T cell activation marker expression as well as death receptor 
expression were not affected by transfection. Thus, activation induced changes in 
transfected EL4 and Jurkat cells can be considered to rely on de novo expression of 
CD44 and CD49d, respectively. 
 
3.1.5 CD44 and CD49d are engaged in leukocyte migration 
CD44 and CD49d both can contribute to leukocyte migration and cooperative activity 
of CD44 and CD49d have been described to strengthen migratory activity. To control 
for the relevance of CD44-CD49d co-operativity in leukocyte migration, the impact of 
anti-CD44 and anti-CD49d on EL4 and Jurkat cells and as control on naïve and AA 
LNC, was evaluated. Migration was tested in Boyden chambers using hyaluronic acid 
(HA), fibronectin (FN) or PMA as stimulus. 
Control LNC displayed a lower migratory activity than AA LNC, which was more 
strongly inhibited by anti-CD44 than anti-CD49d, though both antibodies exerted a 
significant effect. The inhibitory effect was stronger in response to HA and FN than 
BSA. This accounted particularly for anti-CD49d in response to FN (Fig.7A). 
Transfection of EL4 with CD49d exerted no measurable impact on the migratory 
activity towards BSA. However, transfection of Jurkat cells with CD44 increased the 
migratory activity. Migration of non-transfected EL4 and mutCD49d transfected EL4 
cells was only inhibited by anti-CD44. Similarly, only migration of CD44 wt 
transfected Jurkat cells was inhibited by anti-CD44 (Fig.7B). Irrespective of the 
stimulus, the migratory activity of EL4 cells was not influenced by CD49d cDNA 
transfection. However, EL4-CD49d, but not EL4 and EL4-mutCD49d cell migration 
was significantly inhibited by anti-CD44 and anti-CD49d, anti-CD49d being most 
efficient in response to FN (Fig.7C). Independent of the stimulus, migration of 
untransfected and transfected Jurkat cells was inhibited by anti-CD49d. Distinct to 
EL4-mutCD49dcells, migration of Jurkat-mutCD44 and Jurkat-truncCD44 cells was 
partly inhibited by anti-CD44 (Fig.7D). 
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Figure7. Migration of the transfected EL4 and Jurkat cell lines: EL4, EL4-CD49d, El4-mutCD49d, 
Jurkat, Jurkat-CD44, Jurkat-mutCD44, Jurkat-truncCD44 cells and LNC  (5X104) were incubated with 
anti-CD44 or anti-CD49d, washed and seeded in triplicate in the upper well of a Boyden chamber, the 
lower well contained BSA, Hyluronic acid (HA), Fibronectin (FN) or PMA. After incubation for 4hrs 
at 37ο C, 5% CO2, cells in the lower chamber were counted. The percentage of migrating cells is shown 
(mean±SD of three separate experiments). 
 
To control, whether migration and inhibition of migration may be influenced by 
altered adhesion molecules expression due to stimulation with matrix proteins and 
PMA, adhesion molecule expression was evaluated in naïve and AA LNC, non-
transfected and transfected EL4 and Jurkat cells after stimulation on HA, FN or by 
PMA/Ionomycin. Except of a downregulation of CD49c in PMA-stimulated Jurkat 
cells, adhesion molecule expression in EL4 and Jurkat cells remained unaltered. In 
naive and AA LNC, CD44 and CD49d expression increased in HA, FN and PMA 


























Figure8. Expression profile of adhesion molecules in LNC and transfected EL4 and Jurkat cells 
after stimulation: LNC from naïve (control) and AA mice and El4, El4-wtCD49d, EL4-mutCD49d, 
Jurkat, Jurkat-wtCD44, Jurkat-mutCD44, Jurkat-truncCD44 cells were activated on HA or FN coated 
plates and by PMA for 24 hrs follwed by staining with the indicated antibodies. Expression was 
checked by flow cytometry. 
 
Taken together, migration of naive and AA LNC is inhibited by anti-CD44 and anti-
CD49d, though stronger by anti-CD44. In line with this, HA promotes a stronger 
migratory stimulus than FN. Migration of EL4 and Jurkat cells is only inhibited by 
anti-CD44 and anti-CD49d respectively. Furthermore, anti-CD49d inhibits EL4-
CD49d, but not EL4 migration. Jurkat-mutCD44, Jurkat-truncCD44 becomes only 
weakly inhibited by anti-CD44 compared to Jurkat–CD44. From there we conclude 
that in hematopoietic cells CD44 is the major contributor to motility, yet can be 
supported by CD49d. The inefficacy of the extracellular domains of both molecules 
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point towards joint signal transduction rather than towards adhesion strengthening by 
an increase in the docking sites. 
 
3.1.6 Induction of the migratory phenotype is supported by CD44-
CD49d co-operativity 
 
To control for the hypothesis that possibly CD44 and CD49d initiated joint signal 
transduction accounts for strengthened motility, co-immunoprecipitation studies were 
done to get an insight into the CD44 and CD49d association with each other and 
downstream signalling molecules that might affect T cells migration. 
Co-immunoprecipitation confirmed the association of CD44 with CD49d, ezrin, FAK 
and paxillin in Jurkat-CD44 cells. However, co-immunoprecipitation of CD49d with 
CD44 was not observed in Jurkat-mutCD44 and Jurkat-truncCD44 cell lysates, 
similarly co-immunoprecipitation with CD49d showed association with CD44 in 
Jurkat-CD44 and not with Jurkat-mutCD44 and Jurkat-truncCD44 (Fig.9A). CD44 
crosslinking via HA and PMA stimulation strengthend the association of CD44 with 
CD49d, Ezrin and FAK in Jurkat-CD44 cells, but did not suffice mutCD44, 
truncCD44 to associate with CD49d, Ezrine and FAK (Fig.9B).                                                    
 A  
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Figure9.  CD44 and CD49d association: (A) Jurkat, Jurkat-CD44, Jurakt-mutCD44, Jurkat-
truncCD44 cell lysates were immunoprecipitated with anti-CD44and anti-CD49d. Precipitates were 
dissolved by SDS-PAGE. After transfer, associated proteins were detected with the indicated 
antibodies. (B) Jurkat, Jurkat-CD44, Jurakt-mutCD44, Jurkat-truncCD44 cells were activated for 24 hrs 
with PMA or by crosslinking via HA. Cells were lysed and immunoprecipitated with anti-CD44, 
precipitates were dissolved by SDS-PAGE. After transfer associated proteins were detected by western 
blot with the indicated antibodies. 
 
These data provide clear evidence that only CD44 and CD49d co-operativity supports 
T cell and leukemic T cell migration as truncCD44 and mutCD44 which do not 
promote migration, also do not allow CD44 to associate with Ezrin or with CD49d-
associated FAK. 
 
3.1.7 Effect of CD44-CD49d co-operativity on cell proliferation  
Besides its impact on leukocyte migration, CD44 functions as accessory molecule in 
TCR complex-mediated signal transduction and can promote T cell proliferation and 
survival. AA LNC are in activated state and display a significantly increased 
proliferation rate in comparison to naïve LNC. AA LNC responded to HA, but not to 
FN and showed a stronger response to PMA than naïve LNC (Fig10A). When 
comparing the proliferation rate of EL4-CD49d, EL4-mutCD49d and Jurkat-CD44, 
Jurakt-mutCD44, Jurkat-truncCD44, in the absence of a stimulus, no increase in the 
proliferation rate was observed. Also CD44- and /or CD49d-crosslinking on HA or 
FN-coated plates did not suffice for increasing the proliferation rate, irrespective of 
whether only CD44 or CD49d or both, non-mutated molecules were expressed. 
Instead, PMA-treatment led to a sufficient reduction in the proliferation rate, which 
was independent of the transfection with mutated/non-mutated CD44 or CD49d. A 
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similar effect of PMA has been described by Han et al (156). I could only evaluate 
antibody inhibition as a possible indicator of CD44-CD49d cooperativity. Anti-CD44 
effectively reduced the proliferation of EL4-CD49d, but had no or only marginal 
effect on EL4-mutCD49d (Fig10B). Similar observations accounted for Jurkat and 




                                  
 
 
Figure10. Impact of CD44 and CD49d on T cell proliferation: (A) LNC from naïve (control) and 
AA mice and (B) El4, El4-wtCD49d, EL4-mutCD49d cells were activated on HA, FN and by PMA for 
24 hrs and proliferation was checked by 3H-thymidine incorporation. Significant differences in 
proliferation rate after antibody treatment are indicated by *. 
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Our present state of knowledge relies exclusively on antibody inhibition. Nonetheless, 
these data would be in line with cooperativity between CD44 and CD49d also having 
an impact on non-transformed and Leukemic T cell proliferation. I want to mention 
that preliminary evidence points towards CD44-CD49d interaction not to play a major 
role in protecting leukemic T cells from apoptosis as it has been observed in T cells 
(data not shown). This work is ongoing to define signaling pathways that become 
jointly activated via CD44-CD49d ligand binding. 
Additional experiments are required to conclusively answer the question on the 
pathway whereby CD44-CD49d cooperativity promotes T cell proliferation and 
whether this cooperativity suffices for T cell receptor independent T cell proliferation. 
With the tool of EL4 and Jurkat mutated lines, I created, this should be possible and is 
currently pursuate in the lab. 
 
3.2 Myeloid derived suppressor cells as the driving force in the DTH- 
induced cure of AA 
Persisting T cell activation and expansion in autoimmune disease, including AA may 
partly be due to pronounced activity of accessory molecules like CD44 or CD49d, but 
also is promoted by a failure of downregulation of response. As SADBE treatment is 
curative in AA, the comparison of leukocytes of AA and SADBE treated AA mice 
offered itself to see, whether AA leukocytes escape the inherit control mechanisms of 
the immune system including immunosuppression and how a chronic contact eczema 
cope up with these suggested escape mechanisms. 
 
3.2.1 Myeloid derived suppressor cells in AA and chronic contact 
eczema 
Immune responses occur following the initial step of specific antigen recognition and 
the transmission of activating signals. However, upon chronic stimulation, like 
persisting inflammation and /or cancer, immunoregulatory cells become activated. It 
is known that there is a defect in immunoregulatory cells in autoimmune diseases, 
including AA. Thus, it can be speculated that activation of immune regulatory cells by 
a chronic eczema may correct the deficit in AA. Two types of cells are most important 
for regulating T cell responses, Treg and myeloid derived suppressor cells (Gr-1+, 
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CD11b+ MDSC). The latter have been suggested to become particularly expanded and 
activated during chronic inflammation. Thus, I first evaluated the expansion of 
myeloid derived suppressor cells, which negatively affect T cell expansion and 
activation, and are engaged in AA in the therapeutic efficacy of a DTH in AA mice 
(SADBE treated AA mice). I started with the evaluation of MDSC in different 
lymphoid organs of untreated and SADBE treated mice. Gr-1+ CD11b+ cells were 
strongly increased in the spleen of DTH (naive mice treated with SADBE) and AA-
DTH (AA mice treated with SADBE). MDSC also are increased in lymph node cells 
(LNC) and skin infilterating leukocytes (SkIL) in both DTH and AA-DTH mice in 
comparison to the spleen and SkiL of control and AA mice (Fig. 11A-B). 
There are subgroups in MDSC which differ in their activity, therefore it also became 
important to look for the difference between AA and AA/DTH MDSC, since 
differences in the activation status of MDSC in these two groups may play an 
important role in functional activities. 
AA/DTH MDSC express Ly6C at a higher percentage than AA MDSC. In addition, a 
higher percentage of AA/DTH than AA MDSC expresses IL1α and IL6. High TNFα, 
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Figure11. Expression and characterization of MDSC: (A,B) The percentage of MDSC (Gr-1+ 
CD11b+) were double stained and checked via flow cytometry in SC, LNC and SkIL of naïve, AA, 
DTH and AA/DTH mice. The percentage (mean±SD) and the total number of Gr-1+ CD11b+ cells are 
shown. Significant differences in the percentage of spleen cells, SkIL and skin-draining LNC between 
DTH/AA-DTH mice and normal mice are indicated by *. (C) Expression of the indicated markers was 
evaluated by flow cytometry in naïve-, AA-, AA/DTH-MDSC, which were separated according to 
CD11b and Gr1 expression by magnetic beads. Significant differences between AA- and AA/DTH-
MDSC in the percentage of marker+ cells are indicated by *, significant differences in intensity of 
expression are indicated by s. 
 
Expansion of MDSC in DTH and AA/DTH mice points towards a putative role of 
MDSC in the curative action of contact sensitizers. In addition, higher expression of 
STAT1, STAT6 and NFκB expression, which are elevated in AA/DTH-MDSC 
compared to AA-MDSC, is known to be associated with the activated state of MDSC. 
These findings point towards a more activated status of AA/DTH-MDSC. 
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3.2.2 DTH- induced MDSC account for hair re-growth in AA 
  
SADBE treatment induces hair re-growth in AA mice and it has been shown that there 
is an expansion of MDSC in DTH and AA-DTH mice (Fig11A). To confirm that the 
hair growth likely is a consequence of MDSC expansion and activation, mice received 
ATRA (all trans retinoic acid), together with SADBE. ATRA is known for driving 
MDSC into differentiation and therefore MDSC no longer behave as suppressor cells. 
The application of SADBE was repeated weekly and ATRA application was repeated 
once in 3 weeks. ATRA treatment itself exerted no effect. However, when applied 
concomitantly with SADBE only 1 out of 10 mice showed partial hair re-growth, 
whereas 9 out of 10 mice showed partial or complete hair growth during SADBE 
treatment. Also confirming the importance of MDSC, 7 out of 10 AA mice that 
received intravenous (i.v.) injections of MDSC derived from SADBE treated AA 
mice also showed partial hair re-growth, which was prevented by concomitant ATRA 
treatment (Fig.12A). 
Immunohistological studies on skin sections showed that there was a reduction in 
CD4+ and CD8+ T cells in SADBE- and MDSC-treated mice, while no reduction was 
seen in SADBE or MDSC plus ATRA-treated mice (Fig.12B). Instead fewer CD11b+ 
and GR1+cells were detected in ATRA-treated mice (data not shown).  
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 Figure12. MDSC and hair re-growth in AA mice: (A) C3H/HeJ mice with total hair loss 10 week 
after transplantation of AA-affected skin were treated with SADBE, ATRA, SADBE+ATRA, 
AA/DTH MDSC or AA/DTH MDSC+ATRA. The number of mice with partial or total hair re-growth 
is shown. (B) Immunohistology (CD4, CD8) of shock frozen skin section as indicated (White arrows: 
orientation towards the epidermis). 
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Hair re-growth in AA mice after SADBE treatment or after transfer of MDSC and 
suppression of hair re-growth in mice concomitantly receiving ATRA provides a 
strong hint towards a central role of MDSC in the SADBE therapy for AA. To sustain 
this hypothesis, I made a direct comparison of the immune status of lymphocytes 
recovered from AA/DTH mice with the immune status of LNC co-cultured with 
MDSC. 
 
3.2.3 Activation status of T cells in AA and AA/DTH mice and impact 
of MDSC 
 
It has been stated before that T cells in AA are in an activated state and therefore it 
was important to see the effect of SADBE and MDSC on the activation status of these 
cells. It was observed that SADBE treatment exerted no major effect on the 
distribution of leukocyte subpopulations in LNC and SkIL of AA mice. Only CD11b+ 
cells were recovered at a higher level in AA/DTH than AA mice, however the level 
was comparable to that in DTH mice (Fig.13A). To see the impact of MDSC on the 
activation status of T cells, a co-culture system was established, where T cells from 
naïve, AA, DTH and AA/DTH were co-cultured with MDSC derived from naïve, AA, 
DTH and AA/DTH. No significant changes in the percentage of CD4+ and CD8+ LNC 
were observed after co-culture, except for a slight reduction of CD8+ AA and 
AA/DTH LNC after co-culture with AA/DTH- derived MDSC (Fig. 13B).  
Expression of the T cell activation markers CD28, CD69 and CD154 were high in AA 
and AA/DTH LNC and SkIL. Only expression of CD69 was further increased in 
AA/DTH mice compared to AA LNC. Expression of the co-stimulatory molecules 
CD40, CD80 and CD86 was increased in AA LNC and, particularly, SkIL and 
remained high or increased further in AA/DTH LNC (Fig.13C). After co-culture with 
DTH- or AA/DTH-MDSC, the expression of CD28 was slightly, while expression of 
CD69 was strongly reduced in AA (Fig13D). 
 Except for an unexpected reduction in IL-4 and a strong increase in IL-6, there were 
no major DTH-induced changes in cytokine expression in AA LNC and SkIL 
(Fig.13E) and co-culture with MDSC exerted no significant effect. Instead CD152 
and FoxP3 are low in AA LNC and SkIL but are strongly upregulated in AA/DTH 
LNC and SkIL. The latter also accounts for CD25+ cells in LNC and SkIL (Fig.13F). 
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The percentage of CD152+ LNC also increased in co-cultures with DTH- or 

































 Figure13. Activation status of autoreactive T cells in AA, AA/DTH and impact of MDSC: 
(A,C,E,F) LNC and SkIL of naive, AA, DTH and AA/DTH mice were stained with the indicated 
antibodies. Expression was evaluated by flow cytometry .The percentage of stained cells (mean±SD) is 
shown. (B,D,G) Draining LNC of naïve, AA, DTH and AA/DTH mice were co cultured for 48 hrs with 
MDSC from naïve, AA, DTH, AA/DTH mice and were stained with the indicated antibodies. Staining 
of LNC cultured in the absence of MDSC was taken as 100%. A significant decrease or increase in 
marker+ cells as compared to draining LNC and in co-culture with MDSCis indicated by *. 
 
Though SADBE treatment of AA mice does not affect the distribution of leukocyte 
subpopulations, it promotes T cell activation as revealed by up-regulation of 
activation marker CD69 and co-stimulatory molecules CD40 and CD86. While after 
co-culture with DTH- or AA/DTH-MDSC the percentage of the activation marker 
CD69 was significantly reduced.  Instead expression of CD152, which is a negative 
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regulator of T cell activation, was upregulated. Thus, MDSC derived from AA/DTH 
appear potent to control activation of autoreactive T cells. 
 
3.2.4 Regulatory T cells in AA and AA/DTH mice and impact of 
MDSC 
 
Regulatory CD4+CD25+FoxP3+ T cells (Treg) play an important role in maintaining 
homeostasis. Accordingly they are frequently reduced in autoimmune diseases. In 
fact, these are also recovered at a reduced level in AA LNC. Treg were slightly 
increased in AA/DTH LNC, but did not reach the level seen in naïve LNC (Fig.14A). 
Instead, when LNC were co-cultured with DTH- or AA/DTH-MDSC, normal or even 
elevated levels of Treg could be seen (Fig.14B).  
 




Figure 14.The impact of MDSC on regulatory T cells:  (A) LNC were triple stained for CD4, CD25 
and FoxP3. The percentage of triple-positive cells is shown. Significant changes between AA and 
AA/DTH LNC are indicated by *. (B) LNCs were co-cultured with MDSC for 48 hrs and triple stained 
for CD4, CD25 and FoxP3. The percentage of triple positive cells is shown.  Significant changes in Treg 
by co-culture with MDSC are indicated by *. 
 
Co-culture of LNC with MDSC derived from DTH and AA/DTH mice allowed for 
rescuing Treg to a significant level indicating a strong impact of MDSC on Treg 
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expansion and their importance in controlling disease by activation of 
immunosuppression mechanisms, as Treg are important regulatory cells of the immune 
system and that mostly affect activated T cells.  
 
3.2.5 Impact of MDSC on death related marker expression in AA 
effector T cells 
 
Besides the reduction in Treg, autoimmune disease T cells are frequently characterized 
by resistance against activation induced cell death. Nonetheless, in AA, apoptosis 
resistance is unexpected as SkIL and LNC express death receptors CD95L (FAS-L) 
and TNFRI (CD120a) at a high level. However, SADBE treatment further strengthens 
the expression of death receptors like Trail (CD253), TNFα, TNFRI and TNFRII 
(CD120b) (Fig. 15A).After co-culture with AA/DTH MDSC, high CD95L expression 
is further increased (Fig.15B). Both AA- and AA/DTH-MDSC support Trail and 
TNFα expression but only AA/DTH-MDSC support TNFRI and TNFRII expression 
(Fig.15C). TNFRI+ and TNFRII+ LNC were mostly CD4+. Trail was expressed at a 
comparable percentage of CD4+ and CD8+ cells. This distribution was not strikingly 
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Figure15. The Impact of MDSC on death related marker expression in draining LNC and SkIL: 
(A) LNC and SkIL were stained with the indicated antibodies. The percentage of stained cells is 
shown. Significant changes in marker expression in AA/DTH compared to AA LNC or SkIL is 
indicated by *. (B,C) Draining LNC, as indicated, were co-cultured with MDSC for 48 hrs and stained 
for the indicated markers. Staining of LNC cultured in the absence of MDSC was taken as 100%. A 
significant decrease or increase in marker+ cells as compared to draining LNC cultured in the absence 
of MDSC is indicated by *. (D) LNC were double stained with anti-CD4 or anti-CD8 and anti-
CD120a, -CD120b or -CD253. The percentage of double positive cells per CD4+ and CD8+ cells are 
shown. 
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In the presence of DTH or AA/DTH MDSC the percentage of death receptors 
CD95L+, TRAIL+, TNFα+, TNFRI+ and TNFRII+ LNC was strongly increased, 
indicating a possible impact of MDSC on apoptosis induction. 
 
3.2.6 MDSC suppresses AA effector cell proliferation and promotes 
apoptosis 
 
In the absence of an antigen-specific stimulus (10% FCS) as well as in the presence of  
a polyclonal, but TCR-independent stimulus (PMA/Ionomycin), the proliferative 
activity of AA LNC exceeded not only that of naïve and DTH LNC, but also that of 
AA/DTH LNC. This difference became more striking in the presence of AA skin 
lysate that served as surrogate auto-antigen (since alopecia is an autoimmune disease 
of skin affecting hair follicles, autoantigens are expected to be in the hair follicles) 
(Fig.16A), which indicates that SADBE treatment may contribute to an antigen 
unspecific downmodulation of activated T cell proliferation, but possibly is most 
effective in interfering with an antigen specific response. Similarly, in the presence of 
10% FCS, DTH- and AA/DTH-MDSC inhibited AA, DTH and AA/DTH LNC 
(activated LNC) proliferation more efficiently than that of naïve LNC (Fig.16B). To 
support the suggested antigen-specific component of MDSC activity, LNC were co-
cultured with AA/DTH-MDSC in the presence of AA skin lysate or PMA/Ionomycin, 
where the latter circumvents the requirement of TCR engagement. It was observed 
that AA/ DTH-MDSC more efficiently suppressed the response of AA and AA/DTH 
than DTH LNC towards AA skin lysate. However, circumventing the requirement of 
TCR engagement (PMA/Ionomycin) AA/DTH-MDSC suppressed proliferation of 
AA, DTH and AA/DTH LNC with comparable efficacy (Fig.16C).  
Expectedly, AA/DTH-MDSC most efficiently affected the “antigen-specific” 
response of AA and AA/DTH LNC, but additionally exerted TCR-independent 
activity. The activity of MDSC appeared to be contact dependent. Since supernatant 
of MDSC culture for 48hrs under the same conditions did not suppress LNC 
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Figure16. AA and AA/DTH draining LNC distinctly respond to nominal antigen and 
PMA/Ionomycin: (A) 3H-thymidine incorporation of naïve, AA, DTH and AA/DTH LNC in response 
to 10% FCS, AA-skin lysate and PMA/Ionomycin. Significant differences in the response of AA/DTH 
compared to AA LNC are indicated by *. (B, C) Relative 3H-thymidine incorporation of draining LNC 
T cells after 48 hrs of co-culture with (B) MDSC/10%FCS (C) AA/DTH-MDSC/ AA skin lysate or 
AA/DTH-MDSC/ PMA/Ionomycin compared to cultures without MDSC. Values are shown for a ratio 
of T cells: MDSC=10:1. A significant reduction in proliferative activity by MDSC is indicated by *. 
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The proliferative response of AA/DTH LNC is significantly reduced compared to AA 
LNC and MDSC derived from DTH and AA/DTH LNC display stronger suppressive 
activity than MDSC from naïve and AA mice. In addition, there is evidence for 
antigen specificity of response suppression by MDSC (10% FCS versus AA lysate). 
MDSC also suppresses proliferation in response to PMA/Ionomycin. Taken together 
AA/DTH-MDSC most efficiently affected the "antigen-specific" response of AA and 
AA/DTH LNC, but also exerted TCR-independent activity. 
 
To have an insight of apoptosis in AA and AA/DTH mice, LNC from naïve, AA, 
DTH and AA/DTH mice were cultured in RPMI/10% FCS for 48hrs. It was observed 
that the apoptosis rate of AA LNC was significantly lower than that of naïve and DTH 
LNC. The percentage of apoptotic AA/DTH LNC was higher than that of AA LNC, 
but did not reach the level of naïve LNC (Fig.17A). When LNC from naïve, AA, 
DTH and AA/DTH mice were co-cultured with naïve- and AA-MDSC in 
RPMI/10%FCS, no significant increase in the apoptosis rate was seen,but in co-
culture with AA/DTH-MDSC, a slight increase was observed. Instead in the presence 
of PMA/Ionomycin, DTH and AA/DTH MDSC sufficed to strongly mitigate 
apoptosis resistance of AA and AA/DTH LNC. The same tendency, though, less 
pronounced was seen when AA or AA/DTH LNC were co cultured with DTH- or 
AA/DTH-MDSC in the presence of AA skin lysate (Fig.17B, C). To explore whether 
apoptosis resistance relies on CD4+ or CD8+ LNC and in which of these two 
subpopulations MDSC support apoptosis induction, so, it was observed that both 
CD4+ and CD8+ LNC from AA and AA/DTH showed comparable apoptosis 
resistance in presence of 10% FCS. No difference was seen in these two 
subpopulations when co-cultured with AA/DTH MDSC containing AA skin lysate or 
10%FCS, but with PMA/Ionomycin mostly CD8+ cells become apoptotic (Fig.17D). 
Thus MDSC from naïve and AA mice do not promote apoptosis. However, DTH- and 
AA/DTH-MDSC interferes with apoptosis resistance of AA and AA/DTH LNC, 
particularly when cells become stimulated circumventing TCR engagement 
(PMA/Ionomycin). 
These distinct features of AA versus AA/DTH MDSC likely rely on the differences 
between these two populations of myeloid derived cells. As described before, 
AA/DTH-MDSC showed a more activated state similar to that of M-MDSC 
(Monocytic-MDSC), which shows a higher expression of Ly6C. Thus, the highly 
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activated state of AA/DTH MDSC could well provide the fundaments for attacking 
autoreactive T cells. 
 
 
                                                               
          
                                                                                                                                              
 
 
Figure17. The impact of MDSC on apoptosis resistance of AA LNC: (A) LNC were cultured for 48hrs 
in the presence of 10%FCS or PMA/Ionomycin and apoptosis assay was performed using Annexin V-FITC 
and propidium iodide (PI). Early apoptotic cells bind Annexin V and necrotic cells take up PI. Cells were 
incubated in the dark at RT for 15 min and analyzed by flow cytometry using the FL1 channel for 
AnnexinV FITC and FL-3 channel for PI. The percentage of stained LNC is shown. A significant increase 
in apoptosis of AA/DTH as compared to AA LNC is indicated by *. (B) LNC were cultured for 48 hrs in 
the presence of MDSC (LNC: MDSC= 10:1) and 10% FCS or PMA/Ionomycin and were stained with 
AnnexinV-FITC/PI. The percentage of stained LNC is shown. A significant increase in the apoptosis of 
AA/DTH as compared to AA LNC is indicated by *. A significant increase in apoptosis in the presence of 
naïve versus AA/DTH MDSC is indicated by s. (C) LNC were cultured for 48 hrs in the presence of MDSC 
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(LNC:MDSC= 10:1) and AA skin lysate or PMA/Ionomycin and were stained with AnnexinV/PI. The 
relative percentage of stained LNC in comparison to cultures without MDSC is shown. A significant 
increase in apoptosis in the presence of MDSC is indicated by *. (D) AA/DTH LNC were cultured for 48 
hrs in the absence or presence of MDSC and 10%FCS or AA skin lysate or PMA/Ionomycin. The 
percentage of CD4+/AnnexinV+ and CD8+/AnnexinV+ LNC is shown. Significant differences in apoptosis 
susceptibility of CD4+ versus CD8+ LNC are indicated by *. 
 
DTH- and AA/DTH-MDSC display stronger suppressive activity than MDSC derived 
from naive and AA mice and also AA LNC are more severely affected than naive or DTH 
LNC. There is evidence for antigen-specificity of response suppression by MDSC but 
MDSC also suppress proliferation in response to PMA/Ionomycin. The latter particularly 
accounts for the impact of AA/DTH MDSC on apoptosis resistance. 
To sustain these hypotheses, I proceeded to evaluate T cell receptor (TCR) ligation 
initiated signal transduction as well as activation of the extrinsic or the intrinsic pathways 
of apoptosis. 
 
3.2.7 SADBE and MDSC interfere with TCR-initiated signal 
transduction 
ξ chain, a component of the T cell receptor (TCR/CD3) complex essential in T cell 
activation and there is evidence that MDSC can interfere with T cell activation via ξ chain 
downregulation. In freshly harvested AA/DTH LNC a minor reduction in ξ chain+ cells 
was observed (data not shown). In co-culture, naïve- and AA-MDSC exerted no effect 
and DTH-MDSC only had a slight effect on ξ chain expression. The expression of ξ 
chain, except in naïve mice, was significantly reduced in AA, DTH and AA/DTH LNC 
after co-culture with AA/DTH-MDSC in the presence of AA skin lysate.  
To support the interpretation that MDSC accounts for down-regulation of ξ chain 
expression, CD4+ and CD8+ LNC were co-cultured with MDSC.  It was observed that 
DTH- and AA/DTH-MDSC more strongly affected CD4+ than CD8+ ξ chain expression 
(Fig. 18A-C). 
 









                   
              
 
                                                                                         
 
 
Figure18.  The impact of AA/DTH MDSC on ξ chain expression: (A) LNC were cultured for 48 hrs 
in the absence or presence of MDSC (LNC: MDSC= 10:1) and AA skin lysate. The percentage of ξ 
chain+ LNC was evaluated by flow cytometry. (B, C) LNC were cultured as described in A, cells were 
double stained for CD4 or CD8 and ξ chain. The percentage of CD4+ ξ + and CD8+ ξ + LNC is shown. 
(A-C)  A significant decrease in the percentage of ξ +cells by co-culture with MDSC is indicated by *. 
 
In the presence of surrogate autoantigen (AA skin lysate) DTH and AA/DTH MDSC 
promote more efficiently CD4+ than CD8+ ξ chain reduction. 
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There was no strong effect on ξ chain expression by SADBE or AA/DTH-MDSC. 
However, high level of the T cell signaling molecules (Scheme 12) lck, ZAP-70, c-jun 
and ERK1,2 phoshphorylation in AA LNC were significantly reduced in AA/DTH 
LNC as revealed by flow cytometry and western blot analysis (Fig. 19A-D).  
                    
Scheme12. T cell signaling components: T cell receptors are clustered by binding to peptide-
MHC complexes on an antigen-presenting cell,  This brings the Src-like cytoplasmic tyrosine kinase 
lck/fyn into the signaling complex and activates it. Activated, lck phosphorylates tyrosines on the ζ and 
ε chains of the CD3 complex, which now serve as docking sites for another cytoplasmic tyrosine kinase 
called ZAP-70. lck phosphorylates, and thereby activates, ZAP-70. ZAP-70 then phosphorylates 
tyrosines on the tail of another transmembrane protein, which then serve as docking sites for a variety 
of adaptor proteins and enzymes. These proteins then help relay the signal to the nucleus and other 
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Figure19. TCR associated signal transduction in AA/DTH LNC: (A,B) Phosphorylation of Zap-70, 
lck, c-jun and ERK1,2 was evaluated in freshly harvested LNC from naïve, AA, DTH and AA/DTH mice 
by flow cytometry and western blot. (A) Significant differences in the percentage of phosphorylated 
protein expression in AA and AA/DTH versus naïve LNC are indicated by s; significant differences 
between LNC from AA versus AA/DTH are indicated by *. (C, D) Ratio of phosphorylated to non- 
phosphorylated molecules in AA and AA/DTH LNC as revealed by Flow cytometry (C) and western blot 
(D). Significant differences between AA/DTH versus AA LNC(C) and proteins (D) are indicated by *.  
 
Activation of lck, Zap-70, c-jun and ERK1, 2 is impaired in AA/DTH LNC compared 
to AA LNC. 
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A similar picture emerged when LNC were co cultured with MDSC. Phosphorylation 
of ZAP-70, lck, c-jun and less pronounced, ERK1,2 was impaired in AA and 
AA/DTH, but not naïve LNC, when cultured in the presence of AA/DTH-MDSC. On 
the other hand, naïve-MDSC hardly exerted any effect (Fig.20A, B). Calculating the 
ratio of LNC expressing phosphorylated ZAP70, lck, c-jun and ERK1,2 as well as 
calculating the relative protein amount confirmed the strong effect of AA/DTH- 
MDSC on TCR signaling pathway activation, where AA and AA/DTH LNC were 
most and naïve LNC least sensitive to AA/DTH-MDSC ( Fig 20C,D). 
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 Figure20. Impact of AA/DTH MDSC on TCR-associated signal transduction: (A,B) LNC were 
co-cultured with MDSC for 48hrs (LNC: MDSC = 10:1). Expressions of non-phosphorylated and 
phosphorylated proteins were evaluated by (A) flow-cytometry and (B) western blot. (A) Significant 
differences in the ratio of phosphorylated to non-phosphorylated proteins in dependence on the 
presence of MDSC are indicated by *. (C, D)  The ratio of phosphorylated to non-phosphorylated 
proteins was evaluated by flow cytometry (C) for LNC (Flow cytometry) and (D) proteins (WB) in 
cultures containing naive or AA/DTH-MDSC. Significant differences between AA/DTH versus AA 
LNC (C) and proteins (D) are indicated by *. 
 
Taken together activation of lck, Zap70, c-jun and ERK1, 2 is impaired in AA/DTH 
LNC compared to AA LNC. AA/DTH MDSC promote ξ-chain reduction, but more 
efficiently mitigate lck, ZAP70, c-jun and, less pronounced ERK1, 2 activation. 
Thus, SADBE and AA/DTH-MDSC strongly inhibit sustained activation of signaling 
cascades promoting T cell proliferation. ζ-chain internalization which is initiated by 
AA/DTH-MDSC only, is likely contributing to impaired ZAP70 phosphorylation. 
However, the more striking reduction in Lck phosphorylation which is upstream of ξ-
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3.2.8 MDSC participates in breaking apoptosis resistance 
AA effector cells are strongly resistant to apoptosis despite of high level expression of 
death ligands and CD120a. In addition, AA- and AA/DTH-MDSC promote TNFα and 
Trail, only AA/DTH-MDSC promotes CD120a (TNFRI) and CD120b (TNFRII) 
expression. This may correspond to higher apoptosis susceptibility of AA and 
AA/DTH LNC when co-cultured with AA/DTH MDSC, particularly in the presence 
of PMA/Ionomycin. However, PMA/Ionomycin should rather promote T cell 
proliferation. Therefore it became important to unravel the mechanism of this TCR-
independent break of apoptosis resistance supported by MDSC. Evaluation of 
expression of major anti-apoptotic protein (Scheme 13) was done. 
 
 
Scheme13. Apoptotic pathways 
 
It was observed that in freshly harvested LNC from naïve, AA and AA/DTH mice, 
revealed upregulation of p-Akt, p-Bad, Bcl2 and Bcl-Xl in AA compared to naïve 
LNC. As demonstrated by flow cytometry and western blots, Akt and Bad 
phosphorylation was reduced in AA/DTH LNC, but Bcl2 and Bcl-Xl expression was 
not reduced (Fig.21A-D). 
 




    C                                                                                  D 
                                                         
                                           
 Figure21. Impact of SADBE on anti-apoptotic protein expression: (A, B) Anti-apoptotic protein 
expression evaluated in draining LNC by (A) flow cytometry and (B) WB. Significant differences in 
the percentage of stained AA/DTH compared to AA LNC are indicated by *. (C, D) The ratio of the 
anti-apoptotic proteins in AA/DTH compared to AA LNC as revealed by flow cytometry (C) and 
western blot (D). Significant differences between AA/DTH versus AA LNC (C) and proteins (D) are 
indicated by *. 
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Similarly, in the presence of AA skin lyaste AA/DTH MDSC interfered with Akt and 
Bad phosphorylation, but had no effect on Bcl2 and Bcl-Xl. In the presence of 
PMA/Ionomycin, AA/DTH MDSC rather promoted than suppressed Bcl2 and Bcl-Xl 
expression (Fig.22A, B). The ratios of cells expressing phosphorylated versus non-
phosphorylated Akt or Bad and the ratio of Bcl2 and Bcl-Xl versus actin as well as the 
corresponding relative protein band intensities are summarized for AA LNC cultured 
in the presence or absence of AA/DTH MDSC, supplemented with AA skin lysate or 
PMA/Ionomycin (Fig.22C).    
A                                                                           
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Figure22. Impact of MDSC on anti-apoptotic protein expression:  (A, B) Expression of anti-
apoptotic proteins in LNC after co-culture with MDSC (LNC: MDSC= 10:1) in the presence of AA-
skin lysate or PMA/Ionomycin as revealed by (A) flow-cytometry and (B) WB.  Significant differences 
in anti-apoptotic protein expression in dependence on the presence of MDSC are indicated by *. (C) 
The ratios of  phosphorylated versus non-phosphorylated marker proteins  or marker proteins versus 
actin were evaluated in AA LNC, for co-cultures with naïve- versus AA/DTH-MDSC in the presence 
of AA lysate and PMA/Ionomycin. Significant differences in the relative expression intensity of anti-
apoptotic proteins in cultures containing AA/DTH- versus naïve- MDSC are indicated by *.. 
 
SADBE treatment is accompanied by a significant reduction in anti-apoptotic 
proteins. The impact of MDSC varies depending on the donor and the stimulus. 
AA/DTH-MDSC more efficiently than naïve-MDSC, suppresses Akt and Bad 
phosphorylation in the presence of AA skin lysate. In the presence of 
PMA/Ionomycin suppression becomes weaker and expression of Bcl2 and BclXl is 
strengthened. 
 
SADBE and AA/DTH-MDSC efficiently interfere with Akt activation and Bad 
phosphorylation, but do not cope with high level Bcl2 and BclXl expression. Thus, 
downregulation of anti-apoptotic proteins may not contribute to a major degree to 
AA/DTH-MDSC-induced apoptosis susceptibility of AA LNC. Alternatively, 
SADBE and /or AA/DTH-MDSC may promote pro-apoptotic molecule expression 
and activation. 
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Expression of caspase8, the direct target in receptor-mediated apoptosis, was 
unaltered in AA and AA/DTH. Instead, Bid, Bax, Smac, cytochrome C, cleaved 
caspase9 and caspase3 expression were significantly increased in AA/DTH compared 
to AA LNC (Fig.23A-D).  
            
                                                            
             C                                                            D                                                                 
                                         
 
Figure23. Impact of SADBE on pro-apoptotic protein expression: (A, B) Pro-apoptotic protein 
expression was evaluated by flow cytometry (A) and WB (B). (A) Significant differences in pro-
apoptotic protein expression in AA/DTH compared to AA LNC are indicated by *. (C, D) The cell and 
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protein ratio in AA/DTH versus AA LNC lysates as revealed by flow cytometry (C) and Western Blot 
(D). Significant differences between AA/DTH versus AA LNC (C) and proteins (D) are indicated by *. 
 
Upregulation of pro-apoptotic molecules engaged in the mitochondrial apoptosis 
pathway in AA/DTH LNC pointed towards AA/DTH-MDSC possibly activating pro-
apoptotic molecules in AA LNC. Bid, Bax, cleaved caspase9, caspase3 were 
expressed a higher percentage of AA and AA/DTH LNC, when co-cultured in the 
presence of PMA/Ionomycin with AA/DTH- than with naïve-MDSC (Fig.24A). This 
also accounted for Bax, cytochrome C, Smac, cleaved casp9 and casp3 protein levels 
(Fig.24B). Calculating the protein ratios for AA LNC confirmed upregulated 
expression of molecules engaged in the mitochondrial apoptosis pathway in co-
cultures with AA/DTH-, but not naive-MDSC (Fig.24C). Similar, but less pronounced 
effects were seen in co-cultures containing AA skin lysate (data not shown). 
 
                        










                                                                                          
                                          
Figure24. Impact of MDSC on pro-apoptotic protein expression: (A, B) Expression of pro-
apoptotic proteins in LNC after co-cultured with MDSC (LNC: MDSC =10:1) in the presence of 
PMA/Ionomycin as revealed by flow cytometry (A) and WB (B) NT: not tested. (C)  The ratios of pro-
apoptotic marker expressing AA LNC and proteins were evaluated for co-cultures with AA/DTH 
versus naïve MDSC in the presence of PMA/Ionomycin. Significant differences in protein expression 
between AA/DTH- versus naive MDSC are indicated by *. 
 
Taken together, SADBE and AA/DTH-MDSC are not very effective in counter-
regulating high level anti-apoptotic protein expression in AA LNC, but most 
efficiently promote activation of the mitochondrial apoptosis pathway 
 
A chronic dermal DTH reaction supports induction and recruitment of highly efficient 
myeloid derived suppressor cells. A co-culture system provided evidence that reduced 
responsiveness of T cells relates to impaired activation of TCR-associated signaling 
cascades that only partly can be explained by ξ-chain downregulation. More 
importantly SADBE and AA/DTH-MDSC efficiently break autoimmune T cell 
apoptosis resistance by downregulation of anti-apoptotic proteins. They also support 
expression and stimulation of pro-apoptotic proteins.  
C
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4: Discussion 
Alopecia areata is a T cell-mediated autoimmune disease of the skin that affects 
anagen stage hair follicle, and does not become life-threatening (257). The human 
disease is closely mimicked by C3H/HeJ mice that develop AA spontaneously or after 
the transfer of full thickness skin grafts from AA affected mice. The mild disease state 
as well as the availability of an animal model makes this autoimmune disease unique 
inasmuch as these features permit to elaborate the complex immune interactions 
promoting the persistence/exacerbation of an autoimmune disease without an 
iatrogenic or late stage autoimmune disease-associated collapse of the immune 
system. Taking in account the classical autoimmune disease features of AA, 
expansion and activation of autoreactive T cells, reduction in Treg, apoptosis 
resistance, this autoimmune disease model is well suited to define the molecular 
pathways of disease maintenance/progression and also should allow elaborating 
therapeutics interventions that could be of general validity in organ-related 
autoimmune disease. 
I used this model to elaborate the molecular mechanisms, whereby a chronic eczema 
acts as the most efficient therapeutics in AA. Yet, before attending this, I wanted to 
shed more light on another feature of autoimmune T cells, their persistent activation 
and expansion. 
 
4.1 Undue T cell activation and expansion in autoimmune disease 
T cells respond to an antigenic stimulus that is mediated by TCR-complex. After 
antigen elimination, responding T cells can be driven into activation induced cell 
death (AICD) or return to the resting state due to antigenic deficiency or may became 
shut-off by transient internalization of the entire TCR/CD3 complex. All of these 
mechanisms can be disturbed in autoimmune disease. In addition, T cells may become 
activated independent of the TCR/CD3 complex. This phenomenon has been 
described to be mostly mediated by so called accessory molecules, the most important 
one being CD18. We described that CD44 can fulfill similar activities. Interestingly, 
previous work in our lab indicated that this kind of TCR/CD3 complex-independent T 
cell activation may also play a role in AA. This work also revealed that CD44 can co-
operate with CD49d (integrin) in undue T cell activation. In the first part I have tried 
to approach this question at the molecular level. 
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4.1.1 Involvement of CD44-CD49d association in AA 
The involvement of CD44 in autoimmune disease is well known. CD44 plays an 
important role in leukocyte extravasation in autoimmune disease and allergic reaction 
and has been implicated in the processes associated with changes in T cell 
morphology. Originally CD44 has been described as adhesion molecule mediating 
lymphocyte homing. CD44 is also important for the adhesion of leukocytes to 
endothelial cells as an initial step before extravasation. Adhesion of CD44 to its 
ligand(s) induces up-regulation of additional adhesion molecules, mostly integrins 
that strengthen adhesion. In line with this, the CD44-CD49d association supports 
leukocytes’ firm adhesion to vessel endothelium. CD44 associates with CD49d in the 
membrane of activated T cells through its cytoplasmic tail and in vivo this receptor 
combination can regulate T cell extravasation into the peritoneum after induced 
inflammation (258,259). 
It has been described that CD44 associates with src kinases like lck in glycolipid 
enriched membrane (GEM). Furthermore, CD44 and CD49d associate with each other 
via adaptor or signal transducing molecules. In fact CD44 crosslinking can induce 
FAK (Focal adhesion kinase) phosphorylation (Scheme 14) (260) and CD49d can 
promote c-src activation independent of FAK (261). 
The safest way to prove the relevance of the CD44-CD49d interaction in T cell 
activation is by using T cell lines or leukemic lines that differ in absence or presence 
of one of these two molecules, and to transfect these lines with the missing partner 
molecule with or without mutation. In the latter case mutation should be selected such 
that the two molecules can no longer interact with each other. This has been my 
starting point, Jurkat leukaemic line was transfected with CD44, CD44 mutated at 
Ser325 and Ser291 which prohibit ezrin binding, and CD44 without the cytoplasmic 
domain, which prohibit cytosolic signalling. EL4 T cell line was transfected with 
CD49d and CD49d mutated at Ser988 which prohibit paxillin binding. 
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Scheme14. CD44-CD49d association: Ligation of CD44 (e.g., through HA) can facilitate 
aggregation of CD44-integrin-kinase signaling components in lipid rafts. Src family kinases, such as 
Lck, associate with the cytoplasmic tail of CD44 and activate signaling pathway which can strongly 
influences lymphocytes activation and function. 
 
4.1.2 The CD44-CD49d complex promotes T cell motility 
Activated T cells display a migratory phenotype, where migration can be inhibited by 
both anti-CD44 and anti-CD49d. The importance of this co-operation was confirmed 
by increased motility of CD44 transfected Jurkat (CD49d+) and CD49d transfectred 
El4 (CD44+) cells. T cell motility requires the cytoplasmic tail of CD44 to form an 
association with ezrin, which acts as a linker and links CD44 to F-actin (262), 
Furthermore; ezrin binding requires an exchange of Ser325 versus Ser291 
phosphorylation. Therefore, as expected, Jurkat-truncCD44 (without cytoplasmic tail) 
and Jurkat-mutCD44 (Ser291and Ser325) had a lower migration rate. Similarly in 
EL4-mutCD49d less migration was observed since phosphorylation of S988 is 
required for CD49d mediated migration and affects paxillin binding, which in turn 
affects FAK binding. 
Thus, from the functional point of view, the two cell lines transfected with non-
mutated or mutated CD44 and CD49d fully support the engagement of CD44 and 
CD49d in T cell motility as well as the additional requirement of ezrin, paxillin and 
FAK. Co-immunoprecipitation with CD44 and CD49d studies revealed that no 
association between CD44 and CD49d was observed in the cell lines transfected with 
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truncCD44, mutCD44 and mutCD49d. Immunoprecipitations with CD44 on Jurkat-
CD44, Jurkat-mutCD44, Jurkat-truncCD44 revealed that association with ezrin, FAK 
and paxillin was observed only in the Jurkat-CD44 but fails to show any association 
in mutated or truncated CD44 which was cross confirmed by immunoprecipitation 
with CD49d. Thus, the association of CD44 and CD49d is essential for downstream 
with ERM proteins as well as paxillin and FAK which allows for the migration 
Taken together only the activated form of CD44 can associate with CD49d. Both, the 
cytoplasmic tail and ezrin binding are essential to promote the shift towards a mobile 
phenotype. 
 
4.1.3 The CD44-CD49d association promotes leukocyte proliferation 
Particularly CD44 also has been described to act as an accessory molecule in TCR 
complex mediated signal transduction (243). Thus, the question arose whether CD44 
in combination with CD49d also suffice to initiate downstream of the TCR/CD3 
complex activation cascade independent of the TCR/CD3 complex engagement. 
Particularly the EL4 thymoma line, which does not express the TCR and CD3 
complex, was well suited to answer this question. El4-CD49d showed higher rate of 
proliferation which was inhibited by both anti-CD44 and anti-CD49d, while EL4-
mutCD49d showed lesser proliferation and was inhibited only in presence of anti-
CD44 (TCR independent). In Jurkat-CD44mut, Jurkat-CD44trunc showed less 
proliferation, which was inhibited by anti-CD49d only instead Jurkat-CD49d showed 
a higher proliferation rate which was equally inhibited by both anti-CD49d and anti-
CD44. Thus, CD44 and CD49d association is important for the proliferation of the T 
cells and at this point I clould define this only the basis of antibody blockade but this 
work is ongoing to look for the signal cascade.  
From above data it can be speculated that the CD44-CD49d association supports 
TCR/CD3 initiated activation, but can also promotes TCR/CD3 independent 
activation and proliferation. The molecular pathway of signal transduction underlying 
the co-operativity of TCR with CD44-CD49d remains to be explored. In addition the 
impact of CD44-CD49d association on activation induced cell death (AICD) is yet to 
be defined. Further work is needed on this aspect such that it can provide an answer to 
the mechanism underlying the persisting activation and proliferation of autoreactive T 
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cells in autoimmune disease. Blockade of these bystander pathways could be a 
therapeutic approach in autoimmune disease including alopecia. 
 
4.2 Autoimmunity: T cell regulation and a chronic DTH as therapy 
Autoimmunity is characterized, besides undue persisting activation, by resistance 
against apoptosis induced cell death and a deficit in immunoregulatory elements, 
particularly regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC). 
Furthermore, it has been suggested that chronic eczema may be a therapeutic due to 
its impact on the activation and expansion of MDSC. 
 
4.2.1 Characterization of MDSC 
Treatment of AA mice with SADBE results in an expansion and activation of myeloid 
derived CD11b+Gr1+ suppressor cells (MDSC). MDSC are characterized by their 
myeloid origin, immature state and most importantly by their potent ability to 
suppress different aspects of immune responses especially T cell proliferation and 
activation. MDSC were enriched in dermis and spleen of AA mice treated with 
SADBE (AA/DTH). Spleen of SADBE treated mice also contained an increase 
number of activated CD11b+ macrophages. In line with other reports (263), these 
activated macrophages were not suppressive and could even weaken the efficacy of 
MDSC suppression (180). Characterization of MDSC in AA and AA/DTH mice 
showed that AA/DTH-MDSC expressed Ly6C at a higher level which is a 
characteristic of M-MDSC (Monocytic-MDSC Ly6high). Evidence from various 
laboratories suggests that on a per cell basis M-MDSC has more potent suppressive 
behavior than the G-MDSC (Granulocytic-MDSCLy6C low). Previous work in our lab 
showed that AA/DTH-MDSC also expressed TGFβ (180), which can be involved in 
NO production (150,175) and can be induced by IFNγ (103), which supports MDSC 
activation (264). AA/DTH-MDSC showed an increased expression of STAT1, 
STAT6 and NFkB in comparison to AA-MDSC. STAT1 is the main transcription 
factor activated by IFNγ or IL1β signaling and is implicated in the regulation of NO 
and arginase activity on the other hand STAT 6 is also described as a MDSC marker 
and is responsible for upregulation of arginase activity (172-174) and increased TGFβ 
production by MDSC (175). According to several studies it appears that STAT 1 and 
STAT 6 play an important role in MDSC activation. NFkB is also involved in 
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expansion of MDSC, and plays an important role in signal activation of MDSC and 
acquisition of immune suppression function. M-MDSC is the main population of 
MDSC where the NFkB pathway has been shown to be active (265). AA/DTH also 
showed a higher expression of IL1α and IL6. IL1 α induces accumulation of MDSC 
and enhances their suppressive activity against CD4+ and CD8+ T cells (266), IL6 is 
also involved in expansion and activation of MDSC. Finally, TNFα expression and 
secretion as well as TNFRI (CD120a) and TNFRII (CD120b) expression are up 
regulated in MDSC from AA/DTH mice. 
Taken together MDSC d from AA/DTH mice are in a highly activated and 
suppressive state and thus could well be important in mitigating T cell activation. 
 
4.2.2 The relevance of MDSC in mitigating AA 
SADBE treatment cures alopecia and can be replaced (though slightly less efficient) 
by the transfer of AA/DTH-MDSC (180). It is known that ATRA, a member of 
retinoid family of molecules structurally related to vitamin A, exerts profound effects 
on cell proliferation, induction of differentiation and apoptosis in normal cells and 
cancer cells (115). Previously, it has been demonstrated that all trans retinoic acid 
(ATRA) had a potent activity in eliminating MDSC and drives these into 
differentiation towards mature myeloid cells. Treatment of cancer patients and tumor 
bearing mice with ATRA resulted in substantial decrease of these cells and 
improvement of immune responses (116,267). In our studies it has been shown that 
ATRA treatment prevents hair regrowth when applied along with SADBE or MDSC. 
In line with this the immunohistological studies demonstrate that dermal infiltrates of 
CD4+ and CD8+ cells ,which are a hallmark of AA disease were dramatically reduced 
after MDSC transfer and by  SADBE. But, the infiltration remains unaltered upon 
concomitant treatment. Thus, all these factors points towards an active contribution of 
MDSC to hair re-growth. 
  
4.2.3 Comparing the impact of SADBE and MDSC on leukocyte 
subsets and activation status of AA T cells 
It has been reported previously that AA is characterized by an increase in CD1+ 
(expressed on antigen presenting cells), CD4+ and CD8+ cells in the skin and also 
show an upregulation of T cell activation markers CD28, CD69 and CD154 as well as 
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of co-stimulatory molecules CD40, CD80 and CD86 in SkIL and draining LNC (268). 
Besides an expected increase in CD11b+ cells, SADBE treatment did not induce any 
significant change in the leukocyte subpopulation composition. SADBE treatment 
showed a reduction in IL-4 and a strong increase in IL-6, and also strengthened CD69, 
CD40 and CD86 expression only in lymph node and not in skin. In co-cultures with 
AA/DTH-MDSC, a slight decrease in CD8+ LNC was observed. Unlike SADBE 
treatment, AA/DTH-MDSC resulted in a decrease in the expression of activation 
markers CD28, CD69 and an increase in CD152 (CTLA 4) which transmits an 
inhibitory signal to T cells. CD152 expression was only slightly affected by SADBE 
treatment. Thus, MDSC do not actively eliminate T cell subsets and have no impact 
on co-stimulatory molecule expression by antigen prrsenting cell. However, they 
mitigate expression of accessory molecule on T cells 
Regulatory T cells (Treg) are a specialized subpopulation of T cells that act to suppress 
activation of immune cells and thereby maintain homeostasis of the immune system 
and tolerance to self antigens.The importance of the immunesuppressive potential of 
these cells become obvious in autoimmune disease, where Treg are frequently 
recovered at a reduced level (175). This holds true for AA also (268). Thus expression 
of Treg in AA become of special interest. Treg are defined as CD25+CD4+Foxp3+ cells. 
AA lymph node cells and SkIL displayed a reduced level of CD152 and FoxP3. In 
LNC of AA mice treated with SADBE, the percentage of Treg cells was increased 
significantly, but did not reach the level of naïve LNC. Impact of MDSC on Treg has 
been described (103). In line with this, after co-culture with AA/DTH-MDSC a 
further increase in Treg was observed in AA and AA/DTH lymph nodes which were 
even higher than that of naïve mice lymph nodes. IFNγ, IL10 and CD152 have been 
suggested to be required for Treg induction by MDSC (103). The impact of SADBE 
treatment as well as of MDSC on Treg expansion could provide a first explanation for 
the therapeutic efficacy of a chronic eczema /MDSC in AA.  
Apoptosis resistance of autoimmune T cells is an additional important feature of 
sustaining an autoimmune disease state. Autoimmune T cells were reportedly found to 
be resistant to apoptosis (268). In AA, apoptosis resistance is unexpected as SkIL and 
draining LNC express the death receptor CD95L at an elevated level. Death receptors 
are characterized by a unique intracellular death domain (DD), which is crucial for 
death ligand-induced apoptosis. SADBE and co-culture of LNC with MDSC had only 
slight effect on the expression of CD95L, but expression of other death molecules like 
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TNF (can induce apoptotic cell death) and Trail (TNF-related apoptosis-inducing 
ligand) expression become upregulated by both SADBE treatment and also in co-
culture with AA/DTH-MDSC. Furthermore, expression of TNFRI and TNFRII 
(without a death domain) was also increased after SADBE treatment as well as in co-
culture with AA/DTH MDSC, but not by co-culture of AA-MDSC. These distinct 
features of death receptor expression in AA and AA/DTH LNC rely on the difference 
in the activation status of MDSC in these mice. As described before, MDSC derived 
from AA/DTH mice represents a more activated and are more suppressive sub 
population than that of MDSC derived from AA mice 
 
4.2.4 The impact of MDSC on the activation state of T cells is 
reflected by the potency in suppressing T cell proliferation 
SADBE treatment, as well as, isolated MDSC from SADBE-treated AA mice 
efficiently suppresses AA effector T cell proliferation. Suppression was weakest in 
the absence of a nominal antigen and strongest in the presence of AA skin lysate 
which serves as a surrogate auto-antigen. Two major subsets of MDSC apparently 
have an important role in the antigen-specific versus non-specific nature of immune 
suppression. G-MDSC relies on antigen-specific interaction between MDSC and T 
cells, M-MDSC, which use upregulation of NO and arginase, production of 
immunosuppressive cytokines, and other mechanisms, effectively suppress antigen 
specific as well as antigen-independent T-cell responses. The idea that MDSC-
mediated T-cell suppression occurs in an antigen-specific manner is based on findings 
that antigen-specific interactions between antigen-presenting cells and T cells result in 
much more stable and more prolonged cell–cell contact than nonspecific interactions 
(269-271). Such stable contacts are necessary for MDSC derived ROS and 
peroxynitrite to mediate effects on the molecules on the surface of T cells that render 
the T cells unresponsive to specific antigen. However suppression was also observed 
in presence of PMA/Ionomycin, which argues against an exclusive reliance on T cell 
receptor (TCR)-initiated signaling. There are many ways by which MDSC can 
suppress the activation of T cells. One of the pathways relies on down regulating the 
TCR-associated ξ chain (180,272-274). In absence of ξ chain, CD4+ and CD8+ T cells 
are unable to transmit the required signals for activation.bIt was noticed that SADBE 
treatment did not show any significant down regulation of ξ chain expression in 
                                                                                                                        Discussion       
 123
freshly harvested LNC, but in co-cultures with DTH- or AA/DTH-MDSC there was a 
partial down regulation of the ξ chain predominantly in CD4+ cells. It has been 
observed previously in our lab that upon cross linking of the TCR with anti-ε, a 
stronger down regulation of the ξ chain in CD8+ than CD4+ LNC was observed (180). 
Thus, suggest that the AA skin lysate contains antigenic entities more efficiently 
recognized by CD4+ than CD8+ LNC. However, though ξ chain expression was not 
strongly affected by SADBE, SADBE sufficed for a significant change in the T cell 
signaling components. Activation of T cells brings the Src-like cytoplasmic tyrosine 
kinase lck into the signaling complex and activates it. Once activated, lck 
phosphorylates tyrosines on the ζ and ε chains of the CD3 complex, which now serve 
as docking sites for another cytoplasmic tyrosine kinase called ZAP-70. lck 
phosphorylates, and thereby activates, ZAP-70, ZAP-70 then phosphorylates tyrosines 
on the tail of another transmembrane proteins, which then serve as docking sites for a 
variety of adaptor proteins and enzymes. These proteins then help relay the signal to 
the nucleus and other parts of the cell by activating the MAP kinase, the JNK and the 
NFkB signaling pathways. SADBE, cause a reduction in lck, Zap70, c-jun and less 
pronounced ERK1, 2 phosphorylation. In co-culture of LNC with AA/DTH-MDSC 
there was also a strong reduction in the phosphorylation of lck and thereby control the 
phosphorylation of ZAP- 70 followed by c-jun and ERK1, 2 phosphorylation. 
Because lck activation is upstream of the ξ chain phosphorylation, these findings 
imply that ξ chain down regulation is not the dominating feature in SADBE- and 
AA/DTH MDSC initiated suppression of LNC proliferation. It also should be 
mentioned that one of the major pathways of ξ chain down regulation proceeds via 
Toll like receptor-4 (TLR4) (274), which is defect in C3H/HeJ mice (275). However 
TLR4 may not be essentially required, as in absence of TLR4, known to be important 
in controlling the susceptibility to contact hypersensitivity, contact hypersensitivity is 
not significantly impaired (276). As apparent by the therapeutic efficacy of SADBE 
treatment in AA mice, contact hypersensitivity is also not impaired in C3H/HeJ mice. 
Taken together, the mild down regulation of ξ chain and the strong reduction in lck 
phosphorylation argue for additional inhibitory signals that could have been 
transmitted via up regulated CD152 or via Treg or via not yet defined signals. The 
efficacy of MDSC to suppress LNC proliferation in the presence of PMA/Ionomycin 
also points towards additional immunosuppressive mechanisms. 
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It can be concluded from these studies that, SADBE treatment as well as co–culture 
with MDSC is accompanied by a striking reduction in the activation of signaling 
cascades promoting T cell proliferation. ξ chain down regulation can contribute to 
impaired responsiveness, but does not exclusively account for the observed effects. 
 
4.2.5 SADBE, MDSC and apoptosis resistance of AA effector cells 
As described above autoimmune T cells frequently escape apoptosis i.e. are apoptosis 
resistant. Proliferation stimulating signaling cascades like the Akt pathway has been 
shown to inhibit apoptosis by phosphorylating Bad. AA is characterized by high level 
Akt and Bad phosphorylation and also shows high expression of anti-apoptotic 
proteins Bcl2 and BclXl. 
The phosphorylation of Akt and Bad is downregulated when AA mice were treated 
with SADBE and the same effect was observed in co-cultures with AA/DTH–MDSC, 
both in the presence of nominal antigen i.e. AA skin lysate and in presence of 
PMA/Ionomycin which circumvents the TCR, but there was no change in the 
expression of Bcl2 and expression of BclXl even increased in the presence of 
PMA/Ionomycin. High apoptosis resistance of AA LNC may be supported by high 
expression of anti-apoptotic protein expression and this, to some extent is negatively 
affected by SADBE and MDSC. But counteregulation is not very effective and 
seemingly does not effect Bcl2 and BclXl expression. A possible explanation for this 
could be the high level TNFα secreation by MDSC and upregulated TNFR expression 
in AA and AA/DTH LNC initiating JNK and NFkB activation (277), where the latter 
promotes, besides others, transcription of BclXl (277). On the other hand, TNFR 
engagement can transduce both survival and apoptotic signals (278), where the 
elements accounting for the dominance of one or the other are not yet completely 
unraveled (274). Although there seems to be a balance between survival and apoptotic 
signals also in SADBE treated AA mice, I interpret the findings as indicating a slight 
dominance of pro-apoptotic signaling as most elements of the mitochondrial pro-
apoptotic pathway have been strongly upregulated. SADBE as well by AA/DTH-
MDSC promoted Bid expression (279), which activates Bak and Bax that translocates 
to mitochondrial membrane (280). Bax has been shown to have pore-forming 
capabilities. Following a conformational change, they could form channels or even 
holes in the outer mitochondrial membrane (281) and results in the release of 
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cytochrome c from the mitochondrial intermembrane space. Mitochondrial membrane 
permebilization also results in release of Smac/Diablo (282) a mitochondrial factor 
that can facilitate caspase activation through neutralizing endogenous inhibitors of 
caspases, the inhibitor of apoptosis proteins (IAPs). Cytochrome c is considered to be 
the primary mitochondrial factor in caspase-mediated apoptosis. Together with Apaf-
1 and procaspase-9, cytochrome c forms the apoptosome, which is a potent activator 
of caspase-3. Consecutively, the executioner caspase-3 is recruited to the apoptosome, 
where it is activated by the resident caspase-9. Caspase-3 then cleaves key substrates 
in the cell to produce many of the cellular and biochemical events of apoptosis.  
Taken together, I interpret my findings in the sense that the dominance of SADBE 
and AA/DTH-MDSC initiated pro-apototic signals could well rely on the provision of 
TNFα and on upregulated TNFR-expression. 
 
To summarize, the curative effect of persisting contact eczema predominantly relies 
on induction and recruitment of highly efficient M-MDSC characterized by 
upregulated TNFα expression. MDSC derived from AA/DTH contributes to ξ-chain 
downregulation, but exert additional immunosuppressive features that could proceed 
via Treg, upregulated CD152 or activation of an inhibitor upstream of Lck. Besides 
inhibiting T cell activation, AA/DTH-MDSC also break autoimmune T cell apoptosis 
resistance. Downregulation of anti-apoptotic molecules supports increased apoptosis 
susceptibility; the major contribution relies on the activation of the mitochondrial 
apoptosis pathway, where TNFRI might provide the initial trigger (Scheme 15). In 
view of the strong effects on autoimmune T cell activation and survival, DTH-MDSC 
should be considered a potent therapeutics in organ-related autoimmunediseases.   
 
 
                                                                                                                        Discussion       
 126
                        
Scheme15. MDSC: Mode of action: T cell activation is suppressed by the production of 
arginase and ROS, the nitration of the TCR, cysteine deprivation, and the induction of Tregs. MDSC 
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5: Summary 
Alopecia Areata (AA) is an organ related autoimmune disease affecting anagen stage 
hair follicles and is characterized by a peri- and intrafollicular infiltrate of CD4+ and 
CD8+ T cells. The most effective way of treating AA is the application of contact 
sensitizers like diphencyprone or squaric acid dibutyl ester (SADBE). This topical 
application is refreshed for several months so that a mild form of a chronic eczema is 
persistently maintained. The molecular mechanisms underlying therapeutic efficacy 
of DTH in AA are not known, but evidences suggest a strong expansion of myeloid 
derived suppressor cells (MDSC) that hamper T cell proliferation and activation. 
Alternatively, a blockade of accessory molecules in T cell activation could possibly 
be of therapeutic benefit. CD44 and CD49d being candidate accessory molecules. 
In T cells, CD44 became upregulated during activation. Upregulated expression 
promotes leukocyte migration and proliferation. It has been suggested that these 
activities are jointly performed by CD44 and CD49d, which come into proximity 
during T cell activation. To define the underlying mechanism the CD49d-negative 
EL4 lymphoma line was transfected with CD49d or point mutated CD49d, which 
prohibits phosphorylation and FAK binding. In addition, a CD44-negative Jurkat 
leukaemia line was transfected with murine CD44, point mutated CD44 in the ezrin 
binding site and with a cytoplasmic tail truncated CD44. Untransfected and 
transfected EL4 and Jurkat cells and for comparison native and activated leukocytes 
from alopecia areata mice were evaluated for migratory and proliferative activity. 
Migration of leukocytes, EL4-CD49d and Jurakt-CD44 cells was more and equally 
inhibited by anti-CD44 and anti-CD49d, migration of EL4-CD49dmut and Jurkat-
CD44mut, Jurkat-CD44trunc cells was less affected and only inhibited by anti-CD44 and 
anti-CD49d respectively. Similar phenomena were observed with respect to 
proliferation, clarifying molecular pathway(s) are still being in progress 
It can be suggested from these findings that CD44 and CD49d works in cooperation to 
promote T cell migration, activation and proliferation. The blockade of these 
bystander pathways could be a therapeutic approach in autoimmune disease. 
Another important aspect underlying the curative effect of SADBE treatment in AA 
relies on the expansion and activation of myeloid derived suppressor cells (MDSC). A 
therapeutic effect of the latter was abolished by all trans retinoic acid which drives 
MDSC into differentiation. This finding suggested a central role of MDSC in the 
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SADBE therapy of AA. To prove whether the curative effect of SADBE treatment, 
indeed, relies on MDSC induction, the effect of in vivo SADBE treatment was 
compared with the effect of in vitro co-cultures of AA lymph node cells with MDSC 
derived from SADBE treated AA mice. SADBE as well as MDSC strongly interfered 
with AA LNC proliferation accompanied by weak down regulation of ξ chain, and 
strongly impaired activation of Lck and Zap 70, and less pronounced the c-jun and 
MAPK pathway. The strongest effect was seen in presence of AA skin lysate used as 
surrogate autoantigen. Proliferation was also impaired in the presence of PMA plus 
Ionomycin indicating that SADBE / MDSC act at least partly independent of the TCR 
complex. In fact SADBE /MDSC promoted activation of several proapoptotic 
molecules engaged in the mitochondrial apoptotic pathway and interfered with the 
anti-apoptotic PI3K/Akt pathway. The latter effects strongly correlated with TNFα 
secretion by MDSC and TNFRI expression in AA/DTH lymphocytes. 
Taken together, SADBE treatment results in the expansion of MDSC which impair T 
cell activation and contribute to breaking autoimmune T cell apoptosis resistance via 
promoting activation of pro apoptotic proteins. These activities qualify DTH-MDSC 
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